NZ615883B2 - Pyrimidine cyclohexyl glucocorticoid receptor modulators - Google Patents

Pyrimidine cyclohexyl glucocorticoid receptor modulators Download PDF

Info

Publication number
NZ615883B2
NZ615883B2 NZ615883A NZ61588312A NZ615883B2 NZ 615883 B2 NZ615883 B2 NZ 615883B2 NZ 615883 A NZ615883 A NZ 615883A NZ 61588312 A NZ61588312 A NZ 61588312A NZ 615883 B2 NZ615883 B2 NZ 615883B2
Authority
NZ
New Zealand
Prior art keywords
group
alkyl
compound
pyrimidine
dione
Prior art date
Application number
NZ615883A
Other versions
NZ615883A (en
Inventor
Robin Clark
George Hynd
Nicholas Ray
Mohammad Sajad
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Priority claimed from PCT/US2012/029376 external-priority patent/WO2012129074A1/en
Publication of NZ615883A publication Critical patent/NZ615883A/en
Publication of NZ615883B2 publication Critical patent/NZ615883B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Abstract

Disclosed are (E)-5-(3-trifluoromethylbenzyl)-6-(4-phenyl-cyclohexyl)-1H-pyrimidine-2,4-dione analogues having the general formula (I), wherein the dashed line is absent or a bond; X is selected from the group consisting of O and S; R1 is selected from the group consisting of cycloalkyl, heterocycloalkyl, aryl and heteroaryl, optionally substituted with from 1 to 3 R1a groups; R2 is selected from the group consisting of H, alkyl, alkyl-OR1b, alkyl-NR1bR1c and alkylene-heterocycloalkyl; R3 is selected from the group consisting of H and alkyl; Ar is aryl, optionally substituted with 1-4 R4 groups; L1 is a bond or alkylene; wherein each cycloalkyl group is a saturated or partially unsaturated, monocyclic, fused bicyclic or bridged polycyclic ring assembly, wherein each heterocycloalkyl group contains 1 to 5 heteroatoms selected from N, O, and S, optionally oxidized, wherein each aryl group is a polyunsaturated, aromatic, hydrocarbon substituent which can be a single ring or multiple rings which are fused together or linked covalently, wherein each heteroaryl is an aryl group containing 1 to 4 heteroatoms selected from N, O, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and wherein the nitrogen atom(s) are optionally quaternarised; subscript n is an integer from 0 to 3, and salts and enantiomers, racemates, diastereoisomers, tautomers or geometric isomers thereof. Compounds of formula I include compounds such as (E)-5-(3-trifluoromethylbenzyl)-6-(4-phenyl-cyclohexyl)-1H-pyrimidine-2,4-dione, (E)-5-(2-ethylbenzyl)-6-(4-phenyl-cyclohexyl)-1H-pyrimidine-2,4-dione, (E)-5-(6-dimethylamino-pyridin-2-ylmethyl)-6-(4-phenyl-cyclohexyl)-1H-pyrimidine-2,4-dione, (E)-3-(2-hydroxy-ethyl)-6-(4-phenyl-cyclohexyl)-5-(3-trifluoromethyl-benzyl)-1H-pyrimidine-2,4-dione and (E)-5-(2,3-dichloro-benzyl)-3-(3-morpholin-4-yl-propyl)-6-(4-phenyl-cyclohexyl)-1H-pyrimidine-2,4-dione. Also disclosed is a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound as defined above, for treating a disorder or condition indicating administration of a glucocorticoid receptor modulator, wherein the disorder or condition is a condition such as major psychotic depression, stress disorders, antipsychotic induced weight gain, obesity, diabetes, cardiovascular disease, hypertension, Syndrome X, depression, anxiety, glaucoma, human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS), neurodegeneration, Alzheimer's disease, Parkinson's disease, osteoporosis, frailty, muscle frailty, inflammatory diseases, osteoarthritis, rheumatoid arthritis, asthma, psychosis associated with interferon-alpha therapy, chronic pain, pain associated with astroesophageal reflux disease, postpartum psychosis, postpartum depression, neurological disorders in premature infants, and migraine headaches. alkyl, aryl and heteroaryl, optionally substituted with from 1 to 3 R1a groups; R2 is selected from the group consisting of H, alkyl, alkyl-OR1b, alkyl-NR1bR1c and alkylene-heterocycloalkyl; R3 is selected from the group consisting of H and alkyl; Ar is aryl, optionally substituted with 1-4 R4 groups; L1 is a bond or alkylene; wherein each cycloalkyl group is a saturated or partially unsaturated, monocyclic, fused bicyclic or bridged polycyclic ring assembly, wherein each heterocycloalkyl group contains 1 to 5 heteroatoms selected from N, O, and S, optionally oxidized, wherein each aryl group is a polyunsaturated, aromatic, hydrocarbon substituent which can be a single ring or multiple rings which are fused together or linked covalently, wherein each heteroaryl is an aryl group containing 1 to 4 heteroatoms selected from N, O, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and wherein the nitrogen atom(s) are optionally quaternarised; subscript n is an integer from 0 to 3, and salts and enantiomers, racemates, diastereoisomers, tautomers or geometric isomers thereof. Compounds of formula I include compounds such as (E)-5-(3-trifluoromethylbenzyl)-6-(4-phenyl-cyclohexyl)-1H-pyrimidine-2,4-dione, (E)-5-(2-ethylbenzyl)-6-(4-phenyl-cyclohexyl)-1H-pyrimidine-2,4-dione, (E)-5-(6-dimethylamino-pyridin-2-ylmethyl)-6-(4-phenyl-cyclohexyl)-1H-pyrimidine-2,4-dione, (E)-3-(2-hydroxy-ethyl)-6-(4-phenyl-cyclohexyl)-5-(3-trifluoromethyl-benzyl)-1H-pyrimidine-2,4-dione and (E)-5-(2,3-dichloro-benzyl)-3-(3-morpholin-4-yl-propyl)-6-(4-phenyl-cyclohexyl)-1H-pyrimidine-2,4-dione. Also disclosed is a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound as defined above, for treating a disorder or condition indicating administration of a glucocorticoid receptor modulator, wherein the disorder or condition is a condition such as major psychotic depression, stress disorders, antipsychotic induced weight gain, obesity, diabetes, cardiovascular disease, hypertension, Syndrome X, depression, anxiety, glaucoma, human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS), neurodegeneration, Alzheimer's disease, Parkinson's disease, osteoporosis, frailty, muscle frailty, inflammatory diseases, osteoarthritis, rheumatoid arthritis, asthma, psychosis associated with interferon-alpha therapy, chronic pain, pain associated with astroesophageal reflux disease, postpartum psychosis, postpartum depression, neurological disorders in premature infants, and migraine headaches.

Description

PYRIMIDINE CYCLOHEXYL GLUCOCORTICOID RECEPTOR MODULATORS CROSS—REFERENCES TO RELATED APPLICATIONS
[0001] This application claims priority to US. Provisional Application No. ,289, filed March 18, 201 1, which is incorporated in its entirety herein for all BACKGROUND OF THE INVENTION In most species, including man, the physiological glucocorticoid is cortisol (hydrocortisone). Glucocorticoids are secreted in response to ACTH (corticotropin), which shows both circadian rhythm variation and elevations in response to stress and food. Cortisol levels are responsive within minutes to many physical and psychological stresses, including trauma, surgery, exercise, anxiety and depression. Cortisol is a steroid and acts by binding to an ellular, glucocorticoid receptor (GR). In man, glucocorticoid receptors are present in two forms: a ligand-binding GR—alpha of 777 amino acids; and, a GR-beta isoform which s in only the last fifteen amino acids. The two types of GR have high affinity for their specific ligands, and are considered to function through the same transduction pathways.
The biologic effects of cortisol, including those caused by ortisolemia, can be modulated at the GR level using or modulators, such as agonists, partial agonists and antagonists. Several different classes of agents are able to block the physiologic effects of GR-agonist binding. These antagonists include compositions which, by binding to GR, block the y of an t to effectively bind to and/or activate the GR. One such known GR antagonist, mifepristone, has been found to be an effective anti-glucocorticoid agent in humans (Bertagna (1984) J Clin. Endocrinol. Metab. 59:25). Mifepristone binds to the GR with high affinity, with a dissociation constant (Kd) of 10'9 M (Cadepond (1997) Annu. Rev.
Med. 48:129).
In addition to cortisol, the biological effects of other steroids can be modulated at the GR level using receptor modulators, such as agonists, partial ts and nists.
When administered to subjects in need f, steroids can provide both intended therapeutic effects, e. g., by stimulating orticoid receptor transrepression, as well as negative side effects, e. g. by chronic glucocorticoid receptor transactivation. What is needed in the art are new compositions and methods for modulating GR receptors. Similarly, the present ion meets these and other needs.
BRIEF SUMMARY OF THE INVENTION [0004a] A first aspect of the invention provides for a compound of a I: R2 L1 R1 X N (I) wherein the dashed line is absent or a bond; X is selected from the group consisting of O and S; R1 is selected from the group consisting of C3-12 cycloalkyl, C3-20 heterocycloalkyl, aryl and heteroaryl, optionally substituted with from 1 to 3 R1a ; each R1a is independently selected from the group consisting of H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C1-6 alkyl-OR1b, halogen, C1-6 haloalkyl, C1-6 haloaloxy, -OR1b, -NR1bR1c, -C(O)R1b, -C(O)OR1b, -OC(O)R1b, -C(O)NR1bR1c, -NR1bC(O)R1c, -SO2R1b, -SO2NR1bR1c, C3-12 cycloalkyl, C3-20 heterocycloalkyl, aryl and heteroaryl; R1b and R1c are each independently ed from the group consisting of H and C1-6 alkyl; R2 is selected from the group consisting of H, C1-6 alkyl, C1-6 OR1b, C1-6 alkyl-NR1bR1c and C1-6 alkylene- C3-20 heterocycloalkyl; R3 is selected from the group consisting of H and C1-6 alkyl; Ar is aryl, optionally substituted with 1-4 R4 groups; each R4 is independently selected from the group consisting of H, C1-6 alkyl, C1-6 alkoxy, halogen, C1-6 haloalkyl and C1-6 haloalkoxy; L1 is a bond or C1-6 alkylene; n each cycloalkyl group is a saturated or partially rated, monocyclic, fused bicyclic or bridged polycyclic ring assembly, (10249821_1):KZA n each heterocycloalkyl group contains 1 to 5 heteroatoms selected from N, O, and S, optionally oxidized, wherein each aryl group is a saturated, aromatic, hydrocarbon substituent which can be a single ring or multiple rings which are fused together or linked covalently, wherein each heteroaryl is an aryl group containing 1 to 4 heteroatoms ed from N, O, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and wherein the nitrogen atom(s) are optionally quaternized, subscript n is an integer from 0 to 3, and salts and enantiomers, racemates, diastereomers, tautomers or geometric isomers [0004b] A second aspect of the invention provides for a pharmaceutical composition comprising a pharmaceutically able excipient and a compound of the first aspect of the invention. [0004c] A third aspect of the invention es for use of a compound of the first aspect of the invention, in the manufacture of a medicament for treating a disorder or condition indicating administration of a glucocorticoid receptor modulator. [0004d] A fourth aspect of the invention es for use of the compound of the first aspect of the invention, in the manufacture of a medicament for treating a disorder or condition indicating administration of a glucocorticoid receptor antagonist. (10249821_1):KZA 821_1):KZA 2012/029376 BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 shows a method of making the compounds of the present invention.
Figure 2 shows an additional method of making the compounds of the present invention.
DETAILED DESCRIPTION OF THE INVENTION I. General The present invention provides nds capable of modulating a glucocorticoid receptor (GR) and thereby ing beneficial therapeutic effects. The compounds include benzyl pyrimidinedione-cyclohexyl-phenyls. The present invention also provides methods of ng diseases and disorders by modulating a GR receptor with the nds of the present invention.
II. Definitions The abbreviations used herein have their conventional meaning within the chemical and biological arts.
Where substituent groups are specified by their conventional chemical ae, written from left to right, they equally encompass the chemically identical substituents that would result from writing the structure from right to left, e.g., ~CH20- is equivalent to -OCH2-.
[0014] As used herein, the term “alkyl” refers to a ht or branched, saturated, aliphatic radical having the number of carbon atoms indicated. For example, C1—C6 alkyl includes, but is not limited to, methyl, ethyl, propyl, butyl, pentyl, hexyl, iso—propyl, iso—butyl, sec—butyl, tert-butyl, etc.
As used herein, the term “alkylene” refers to either a straight chain or branched alkylene of 1 to 7 carbon atoms, i.e. a divalent arbon radical of 1 to 7 carbon atoms; for instance, straight chain alkylene being the bivalent radical of Formula -(CH2)n—, where n is 1, 2, 3, 4, 5, 6 or 7. Preferably alkylene represents straight chain alkylene of 1 to 4 carbon atoms, e.g. a methylene, ethylene, propylene or butylene chain, or the methylene, ethylene, propylene or butylene chain mono—substituted by alkyl rably methyl) or disubstituted on the same or different carbon atoms by C1—C3—alkyl rably methyl), the total number of carbon atoms being up to and including 7. One of skill in the art will appreciate that a single carbon of the ne can be nt, such as in —CH((CH2)nCH3)-, wherein n = 0-5.
As used herein, the term “alkenyl” refers to either a straight chain or branched arbon of 2 to 6 carbon atoms, having at least one double bond. Examples of alkenyl groups include, but are not limited to, vinyl, propenyl, isopropenyl, l-butenyl, 2-butenyl, isobutenyl, butadienyl, l—pentenyl, 2—pentenyl, isopentenyl, 1,3-pentadienyl, 1,4-pentadienyl, l-hexenyl, 2-hexenyl, 3-hexenyl, 1,3-hexadienyl, 1,4-hexadienyl, 1,5-hexadienyl, 2,4— hexadienyl, or 1,3,5—hexatrienyl. Alkenyl groups can also have from 2 to 3, 2 to 4, 2 to 5, 3 to 4, 3 to 5, 3 to 6, 4 to 5, 4 to 6 and 5 to 6 carbons. The alkenyl groups is typically monovalent, but can be divalent, such as when the l group links two moieties together.
As used herein, the term “alkynyl” refers to either a straight chain or branched hydrocarbon of 2 to 6 carbon atoms, having at least one triple bond. es of alkynyl groups include, but are not limited to, acetylenyl, propynyl, l-butynyl, 2-butynyl, isobutynyl, sec—butynyl, butadiynyl, l—pentynyl, 2-pentynyl, isopentynyl, 1,3—pentadiynyl, 1,4- pentadiynyl, nyl, 2—hexynyl, 3—hexynyl, 1,3-hexadiynyl, 1,4—hexadiynyl, 1,5— hexadiynyl, 2,4—hexadiynyl, or 1,3,5-hexatriynyl. Alkynyl groups can also have from 2 to 3, 2 to 4, 2 to 5, 3 to 4, 3 to 5, 3 to 6, 4 to 5, 4 to 6 and 5 to 6 carbons. The alkynyl groups is typically lent, but can be divalent, such as when the alkynyl group links two moieties 2O together.
As used herein, the term "alkoxy" refers to an alkyl radical as described above which also bears an oxygen substituent e of covalent attachment to another hydrocarbon for e, methoxy, ethoxy or t—butoxy group.
As used herein, the term "halogen," by itself or as part of another substituent, means, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom.
As used herein, the term “haloalkyl” refers to alkyl as defined above where some or all of the hydrogen atoms are substituted with halogen atoms. Halogen (halo) preferably represents chloro or fluoro, but may also be bromo or iodo. For example, haloalkyl includes trifluoromethyl, fluoromethyl, 4,5-pentafluoro-phenyl, etc. The term “perfluoro” defines a compound or l which has at least two available hydrogens substituted with fluorine. For example, perfluoromethane refers to 1,1,1-trifluoromethyl.
As used herein, the term “haloalkoxy” refers to alkoxy as defined above where some or all of the en atoms are substituted with halogen atoms. "Haloalkoxy" is meant to include loalkyl(oxy) and polyhaloalkyl(oxy).
As used herein, the term “alkylamine” refers to an alkyl groups as defined within, having one or more amino groups. The amino groups can be primary, secondary or tertiary.
The alkyl amine can be further substituted with a hydroxy group. Alkyl amines useful in the present invention include, but are not limited to, ethyl amine, propyl amine, isopropyl amine, ethylene diamine and ethanolamine. The amino group can link the alkyl amine to the point of attachment with the rest of the compound, be at the omega position of the alkyl group, or link together at least two carbon atoms of the alkyl group. One of skill in the art will appreciate that other alkyl amines are useful in the present invention.
As used herein, the term “cycloalkyl” refers to a saturated or partially rated, monocyclic, fused bicyclic or bridged polycyclic ring assembly containing from 3 to 12 ring atoms, or the number of atoms indicated. For example, C3-C 3 lkyl includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. lkyl also includes nyl and adamantyl.
As used herein, the term “heterocycloalkyl” refers to a ring system having from 3 ring members to about 20 ring members and from 1 to about 5 heteroatoms such as N, O and S. Additional heteroatoms can also be useful, including, but not limited to, B, Al, Si and P.
The heteroatoms can also be oxidized, such as, but not d to, -S(O)- and —. For example, heterocycle includes, but is not limited to, tetrahydrofuranyl, tetrahydrothiophenyl, lino, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperazinyl, piperidinyl, indolinyl, lidinyl and 1,4-di0xa—8-aza-spiro[4.5]decyl.
As used herein, the term “alkylene-heterocycloalkyl” refers to a heterocycloalkyl group, as defined above, which is linked to another group by an alkylene. The heterocycloalkyl and the group to which the heterocycloalkyl is linked by an alkylene can be linked to the same atom or different atom of the alkylene.
As used herein, the term "aryl" means, unless otherwise stated, a polyunsaturated, aromatic, hydrocarbon substituent which can be a single ring or multiple rings (preferably from 1 to 3 rings) which are fused together or linked covalently. Examples include, but are not d to, phenyl, biphenyl, naphthyl, and benzyl.
As used , the term "heteroaryl" refers to aryl groups (or rings) that n from one to four heteroatoms selected from N, O, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quaternized. A heteroaryl group can be ed to the remainder of the molecule through a carbon or heteroatom. Non-limiting examples of aryl and heteroaryl groups include phenyl, l—naphthyl, 2-naphthyl, 4—biphenyl, l—pyrrolyl, 2-pyrrolyl, 3—pyrrolyl, 3-pyrazolyl, 2—imidazolyl, 4- olyl, pyrazinyl, 2—oxazolyl, 4-oxazolyl, 2-phenyl—4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, zolyl, 5-thiazolyl, 2-furyl, 3—furyl, 2-thienyl, 3— thienyl, 2-pyridyl, 3-pyridyl, dyl, 2-pyrimidyl, midyl, 5-benzothiazolyl, purinyl, 2-benzimidazolyl, 5-indolyl, l-isoquinolyl, 5—isoquinolyl, 2-quinoxalinyl, 5—quinoxalinyl, 3— quinolyl, and 6—quinolyl. Substituents for each of the above noted aryl and heteroaryl ring systems are selected from the group of acceptable substituents described below.
For brevity, the term "aryl" when used in ation with other terms (e. g. aryloxy, arylthioxy, arylalkyl) includes both aryl and heteroaryl rings as defined above.
Thus, the term "arylalkyl" is meant to include those radicals in which an aryl group is attached to an alkyl group (e.g, benzyl, phenethyl, pyridylmethyl and the like) including those alkyl groups in which a carbon atom (e.g, a methylene group) has been replaced by, for example, an oxygen atom (e.g, phenoxymethyl, 2—pyridyloxymethyl, 3-(1- naphthyloxy)propyl, and the like). Likewise, the term "heteroarylalkyl" is meant to include those radicals in which a heteroaryl group is attached to an alkyl group.
Each of the above terms (e.g, ," "aryl" and "heteroaryl") are meant to include both substituted and unsubstituted forms of the indicated radical. Examples of substituents for each type of radical are ed below.
Substituents for the alkyl and heteroalkyl radicals (including those groups often referred to as alkylene, alkenyl, heteroalkylene, heteroalkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, and heterocycloalkenyl) can be one or more of a variety of groups selected from, but not limited to: —OR', =0, =NR', =N-OR', —NR'R", -SR', -halogen, —SiR'R"R"', -OC(O)R', -C(O)R', —COZR', -CONR‘R", —OC(O)NR'R", -NR"C(O)R', -NR'—C(O)NR"R"', —NR"C(O)2R’, -NR-C(NR'R"R”')=NR"", —NR—C(NR’R")=NR"‘, ~S(O)R’, —S(O)2R', —S(O)2NR'R", Z)R', -CN and —N02 in a number ranging from zero to (2m'+l), where m’ is the total number of carbon atoms in such radical. R', R", R'” and R"" each preferably independently refer to hydrogen, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or tituted aryl (e. g., aryl substituted with 1—3 ns), substituted or unsubstituted alkyl, alkoxy or thioalkoxy groups, or arylalkyl groups. When a compound of the present invention includes more than one R group, for example, each of the R groups is independently selected as are each R', R", R'" and R"" groups when more than one of these groups is present. When R' and R" are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 4-, 5-, 6-, or 7-membered ring. For example, —NR'R" is meant to include, but not be d to, l—pyrrolidinyl and 4-morpholinyl. From the above discussion of substituents, one of skill in the art will understand that the term "alkyl" is meant to include groups ing carbon atoms bound to groups other than hydrogen groups, such as haloalkyl (e.g., -CF3 and —CH2CF3) and acyl (e.g., H3, -C(O)CF3, H20CH3, and the like).
Similar to the substituents described for the alkyl l, substituents for the aryl and heteroaryl groups are varied and are selected from, for example: halogen, —OR', —NR'R", -SR', -halogen, —SiR'R"R"', —OC(O)R', —C(O)R', —C02R’, -CONR'R", -OC(O)NR'R", —NR"C(O)R', ~NR'-C(O)NR"R"', O)2R', -NR—C(NR'R"R"')=NR"", —NR—C(NR'R")=NR"', -S(O)R', -S(O)2R', —S(O)2NR'R", —NR(SOz)R', -CN and —N02, -R', —N3, -CH(Ph)2, fluoro(C1-C4)alkoxy, and fluoro(C1—C4)alkyl, in a number ranging from zero to the total number of open valences on the aromatic ring system; and where R', R", R"' and R"" are preferably independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, tuted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl. When a compound of the present invention es more than one R group, for e, each of the R groups is independently selected as are each R’, R", R'" and R"" groups when more than one of these groups is present.
Where two substituents are "optionally joined together to form a ring," the two substituents are covalently bonded together with the atom or atoms to which the two substituents are joined to form a substituted or unsubstituted aryl, a tuted or unsubstituted heteroaryl, a substituted or unsubstituted lkyl, or a substituted or unsubstituted heterocycloalkyl ring.
“Salt” refers to acid or base salts of the compounds used in the methods of the present invention. Illustrative examples of pharmaceutically acceptable salts are mineral acid (hydrochloric acid, hydrobromic acid, phosphoric acid, and the like) salts, organic acid c acid, propionic acid, glutamic acid, citric acid and the like) salts, quaternary um (methyl iodide, ethyl iodide, and the like) salts. It is understood that the pharmaceutically acceptable salts are non-toxic. Additional information on suitable WO 29074 pharmaceutically able salts can be found in Remington's Pharmaceutical Sciences, 17th ed., Mack hing Company, Easton, Pa., 1985, which is incorporated herein by reference.
“Hydrate” refers to a compound that is complexed to at least one water molecule.
The nds of the present ion can be complexed with from 1 to 10 water molecules.
“Isomers” refers to compounds with the same chemical formula but which are structurally guishable.
“Tautomer” refers to one of two or more structural isomers which exist in equilibrium and which are readily converted from one form to another.
[0037] As used herein, the phrases “pharmaceutically acceptable excipient” and “pharmaceutically able carrier” refer to a substance that aids the administration of an active agent to and absorption by a subject and can be included in the compositions of the present invention without causing a significant adverse toxicological effect on the patient.
Non-limiting examples of pharmaceutically able excipients include water, NaCl, normal saline solutions, lactated Ringer’s, normal sucrose, normal glucose, binders, , disintegrants, lubricants, coatings, ners, flavors and , and the like. One of skill in the art will recognize that other pharmaceutical excipients are useful in the present invention.
As used herein, the terms “treat”, “treating” and “treatment” refer to any indicia of success in the treatment or amelioration of an injury, pathology or condition, including any objective or subjective parameter such as abatement; remission; diminishing of symptoms or making the injury, ogy or condition more ble to the patient; slowing in the rate of degeneration or decline; making the final point of degeneration less tating; improving a patient's physical or mental well-being. The treatment or amelioration of symptoms can be based on objective or subjective parameters; including the results of a physical examination, neuropsychiatric exams, and/or a psychiatric evaluation.
As used herein, the terms “disorder” or “condition” refer to a state of being or health status of a patient or subject capable of being treated with the glucocorticoid receptor tors of the present invention. Examples of disorders or conditions include, but are not limited to, obesity, hypertension, depression, anxiety, and Cushing's Syndrome.
[0040] As used herein, the phrase “glucocorticoid receptor” (“GR”) refers to a family of intracellular receptors which specifically bind to cortisol and/or cortisol analogs (e.g. dexamethasone). The glucocorticoid receptor is also referred to as the ol receptor. The term includes isoforms of GR, inant GR and mutated GR.
As used herein, the term “modulating a glucocorticoid receptor” refers to methods for adjusting the response of a glucocorticoid receptor towards glucocorticoids, orticoid antagonists, agonists, and partial agonists. The methods include contacting a glucocorticoid or with an effective amount of either an nist, an agonist, or a partial agonist and detecting a change in GR activity.
As used herein, the term “glucocorticoid receptor modulator” refers to any composition or compound which modulates the binding of a glucocorticoid receptor (GR) agonist, such as cortisol, or cortisol analogs, synthetic or natural, to a GR. The tion can include partially or completely inhibiting (antagonizing) the binding of a GR agonist to a GR. A “specific glucocorticoid receptor antagonist” refers to any composition or compound which inhibits any biological se associated with the binding of a GR to an agonist. By “specific,” we intend the drug to preferentially bind to the GR rather than other nuclear ors, such as mineralocorticoid receptor (MR) or progesterone receptor (PR). GR modulators of the present ion include compounds of Formula I below.
As used herein, the term “antagonizing” refers to blocking the binding of an agonist at a receptor molecule or to inhibiting the signal produced by a receptor—agonist. A receptor antagonist blocks or dampens agonist-mediated responses.
[0044] As used , the terms “patient” or “subject” refers to a living organism suffering from or prone to a condition that can be treated by administration of a pharmaceutical composition as provided herein. Non-limiting examples include humans, other s and other non-mammalian animals.
As used herein, the phrase “therapeutically effective amount” refers to an amount of a ated functional agent or of a pharmaceutical composition useful for ng or ameliorating an identified disease or condition, or for exhibiting a detectable therapeutic or inhibitory effect. The effect can be detected by any assay method known in the art.
The terms "a," "an," or "a(n)", when used in reference to a group of substituents or "substituent group" herein, mean at least one. For example, where a nd is substituted with "an" alkyl or aryl, the compound is optionally substituted with at least one alkyl and/or at least one aryl, wherein each alkyl and/or aryl is optionally different. In another example, where a compound is substituted with "a" subsitutent group, the compound is substituted with at least one substituent group, wherein each subsitutent group is optionally different.
Description of compounds of the t invention are limited by principles of chemical bonding known to those skilled in the art. Accordingly, where a group may be substituted by one or more of a number of tuents, such substitutions are selected so as to comply with principles of chemical bonding and to give nds which are not ntly unstable and/or would be known to one of ordinary skill in the art as likely to be unstable under ambient conditions, such as aqueous, neutral, or physiological conditions. 111. Compounds
[0048] In some embodiments, the present invention provides a compound of formula I: (I), wherein the dashed line is absent or a bond. X is O or S. R1 is cycloalkyl, heterocycloalkyl, aryl or heteroaryl, optionally substituted with from 1 to 3 Rla groups. Each Rla is independently H, C1-6 alkyl, C2.6 alkenyl, C2.6 alkynyl, C1.6 alkoxy, C1-6 alkyl-ORlb, halogen, C1_6 haloalkyl, C,_6 haloaloxy, -011”: —NR“’R‘°, —C(O)R1b, -C(O)OR”’, -OC(O)R”’, R1bR1°, —NR1bC(O)R]°, -SOzR]b, —SOzNR1bR1°, cycloalkyl, heterocycloalkyl, aryl or heteroaryl. R1b and R10 are each H or C1-6 alkyl. R2 is H, C1-6 alkyl, C1_6 alkyl-ORIb, C1_6 alkyl—NRle1c or C1_6 alkylene-heterocycloalkyl. R3 is H or C1_6 alkyl. Ar is aryl, optionally substituted with 1—4 R4 groups. Each R4 is H, C1-6 alkyl, C1-6 , halogen, C1-6 haloalkyl or C1_6 koxy. L1 is a bond or C1_6 ne. Subscript n is an integer from 0 to 3. Also ed are the salts and isomers of the compounds recited herein.
In some other embodiments, the present invention provides a compound having formula la: (la).
In some embodiments, L1 is methylene. In other embodiments, Ar is .
In some embodiments, the present invention provides a compound having formula (Ib).
[0052] In some other embodiments, the present invention provides a compound having formula Ic: (Ic).
In some embodiments, the present invention provides a nd wherein R1 is aryl or heteroaryl. In other embodiments, R1 is selected from the group consisting of , pyridyl, pyrimidine, and le. In some other embodiments, each Rla is independently H, C1-6 alkyl, (31-6 alkoxy, halogen, C1-6 haloalkyl, —NR”’R‘°, or -SOzR1b. In still other embodiments, each R121 is C145 haloalkyl. In some other embodiments, each Rla is ndently H, Me, Et, -OMe, F, Cl, —CF3, —NMe2, or —SOzMe. In other embodiments, each R121 is —CF3. In some other embodiments, R2 is H or C1_6 alkyl. In other embodiments, R2 is H.
In some embodiments, the present invention provides a compound selected from the following: 0 0 CI WO 29074 C! Cl CI WO 29074 2012/029376 In some other embodiments, the present invention provides a compound having the formula: The nds of the present invention may exist as salts. The present invention includes such salts. Examples of able salt forms include hydrochlorides, hydrobromides, sulfates, methanesulfonates, nitrates, maleates, acetates, citrates, fumarates, tartrates (eg (+)-tartrates, (—)-tartrates or mixtures thereof including racemic mixtures, succinates, benzoates and salts with amino acids such as glutamic acid. These salts may be prepared by methods known to those skilled in art. Also included are base addition salts such as sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt. When compounds of the t ion contain relatively basic functionalities, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent. Examples of able acid addition salts e those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, ic, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived c acids like acetic, propionic, isobutyric, maleic, malonic, benzoic, ic, suberic, fumaric, , mandelic, phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, methanesulfonic, and the like. Also included are salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like. Certain specific compounds of the present invention contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.
Other salts include acid or base salts of the compounds used in the methods of the t invention. Illustrative examples of pharmaceutically acceptable salts are mineral acid (hydrochloric acid, romic acid, phosphoric acid, and the like) salts, organic acid (acetic acid, propionic acid, glutamic acid, citric acid and the like) salts, and quaternary ammonium (methyl iodide, ethyl iodide, and the like) salts. It is understood that the pharmaceutically acceptable salts are non-toxic. Additional information on suitable pharmaceutically acceptable salts can be found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, which is incorporated herein by reference.
Pharmaceutically acceptable salts includes salts of the active compounds which are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein. When compounds of the present invention contain relatively acidic functionalities, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent. Examples of pharmaceutically able base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt.
When nds of the t invention contain relatively basic functionalities, acid on salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a le inert solvent. Examples of pharmaceutically acceptable acid addition salts e those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, drogenphosphoric, dihydrogenphosphoric, ic, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, lactic, ic, phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, methanesulfonic, and the like. Also included are salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (see, for example, Berge et al., "Pharmaceutical Salts", Journal ofPharmaceutical Science, 1977, 66, 1-19). Certain specific compounds of the present invention contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.
The neutral forms of the compounds are preferably regenerated by contacting the salt with a base or acid and isolating the parent compound in the tional . The parent form of the compound differs from the s salt forms in n physical properties, such as solubility in polar solvents.
[0060] Certain compounds of the present invention can exist in ated forms as well as ed forms, including hydrated forms. In general, the solvated forms are lent to unsolvated forms and are encompassed within the scope of the present invention. Certain compounds of the present invention may exist in multiple crystalline or amorphous forms. In 2012/029376 general, all physical forms are equivalent for the uses contemplated by the present invention and are intended to be within the scope of the present invention.
Certain compounds of the present invention possess asymmetric carbon atoms (optical centers) or double bonds; the enantiomers, racemates, diastereomers, tautomers, geometric isomers, stereoisometric forms that may be defined, in terms of absolute stereochemistry, as (R)-or (S)— or, as (D)— or (L)- for amino acids, and individual isomers are encompassed within the scope of the present invention. The compounds of the present invention do not include those which are known in art to be too unstable to synthesize and/or isolate. The present invention is meant to include compounds in racemic and optically pure forms. lly active (R)— and (S)-, or (D)- and (L)—isomers may be prepared using chiral synthons or chiral reagents, or ed using conventional techniques.
Isomers e compounds having the same number and kind of atoms, and hence the same molecular weight, but differing in respect to the structural arrangement or configuration of the atoms.
[0063] It will be apparent to one skilled in the art that certain compounds of this invention may exist in tautomeric forms, all such tautomeric forms of the compounds being within the scope of the invention. Tautomer refers to one of two or more structural isomers which exist in brium and which are y converted from one isomeric form to another.
Unless ise stated, structures depicted herein are also meant to include all chemical forms of the structure; i.e., the R and S configurations for each asymmetric center. Therefore, single stereochemical s as well as enantiomeric and diastereomeric mixtures of the present compounds are within the scope of the invention.
Unless otherwise stated, the compounds of the t invention may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such nds. For example, the nds of the present invention may be radiolabeled with radioactive isotopes, such as for example deuterium (2H), tritium (3H), iodine-125 (1251), carbon-l 3 (I3C), or carbon-l4 (14C). All isotopic variations of the compounds of the t invention, whether radioactive or not, are encompassed within the scope of the present invention.
[0066] In addition to salt forms, the present invention provides compounds, which are in a prodrug form. Prodrugs of the compounds bed herein are those compounds that readily undergo chemical changes under physiological conditions to provide the compounds of the present invention. Additionally, prodrugs can be converted to the compounds of the t invention by al or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to the nds of the present ion when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent.
The compounds of the present invention can be prepared by a variety of methods known in the art. For example, the compounds can be prepared as shown in Figure 1. In Figure l, the chloro—pyrimidinediones 1 (described in WOO6/014394 and incorporated herein) are coupled with a 4—phenylcyclohex-l -enyl boronate ester in the presence of a Pd catalyst to afford the cyclohexenyl pryimidinediones 2. tic hydrogenation then affords a cis/trans mixture from which the desired trans-isomer 3 can be obtained by conventional separation techniques, e. g., column chromatography.
Compounds 3 can be prepared by the stereospecific synthesis described in Figure 2.
Commercially available trans-4—(4-chlorophenyl)—cyclohexanecarboxylic acid (4) is hydrogenated in the ce of a ium on carbon catalyst in an alcohol, preferably ethanol, to afford transphenyl cyclohexanecarboxylic acid (5). The acid 5 is converted to ketoester 7 by treatment with Meldrum’s acid (6) in the presence of 4—dimethylaminopyridine and dicyclohexylcarbodiimide, ed by heating in ethanol. Alkylation of the ketoester 7 can be accomplished by treatment with a base, such as NaH, and a benzyl halide 8 in a solvent such as tetrahydrofuran to afford the ated ketoester 11. Alternatively, ketoester 7 can be condensed with a benzaldehyde 9 by g in toluene in the presence of acetic acid and piperidine to afford the olefin 10. Catalytic hydrogenation of 10 provides the benzylated ketoester 11. Treatment of 11 with thiourea in ethanol in the ce of sodium ethoxide gives the 2-thioxo—2,3—dihydro—1H-pyrimidin—4—ones 12 which are subsequently converted to the subject compounds 3 by acid hydrolysis, preferably with aqueous chloroacetic acid in dioxane.
Compounds in which R2 is a heteroaryl group are similarly prepared by using a heteroaryl methyl halide or a heteroaryl aldehyde in place of the benzyl halide (8) or benzaldehyde (9) in Figure 2. nds in which R1 are alkyl or substituted alkyl groups can be prepared by treatment of 3 with a base, such as sodium hydride, and the requisite ting agent, preferably an alkyl halide or substituted alkyl halide. 2012/029376 IV. Pharmaceutical Compositions In some embodiments, the present invention es a pharmaceutical composition including a pharmaceutically acceptable excipient and the compound of formula I.
The compounds of the present invention can be prepared and stered in a wide variety of oral, parenteral and topical dosage forms. Oral preparations e tablets, pills, powder, dragees, capsules, liquids, lozenges, gels, syrups, slurries, suspensions, etc., suitable for ingestion by the patient. The compounds of the present invention can also be administered by injection, that is, intravenously, intramuscularly, intracutaneously, subcutaneously, intraduodenally, or intraperitoneally. Also, the compounds described herein can be stered by inhalation, for example, intranasally. Additionally, the compounds of the present invention can be administered transdermally. The GR modulators of this invention can also be administered by in intraocular, intravaginal, and intrarectal routes ing itories, insufflation, powders and aerosol formulations (for examples of steroid nts, see Rohatagi, J. Clin. Pharmacol. 35:1187-1193, 1995; Tjwa, Ann. Allergy Asthma Immunol. 75:107-111, 1995). Accordingly, the t invention also provides pharmaceutical compositions including a pharmaceutically able carrier or excipient and either a nd of Formula (I), or a pharmaceutically acceptable salt of a compound of Formula (I).
For preparing ceutical compositions from the compounds of the present invention, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances, which may also act as ts, flavoring agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material. Details on techniques for formulation and administration are well described in the scientific and patent literature, see, e.g., the latest edition of Remington's Pharmaceutical Sciences, Maack Publishing Co, Easton PA ("Remington's").
In s, the carrier is a finely divided solid, which is in a mixture with the finely divided active component. In tablets, the active component is mixed with the r having the necessary binding properties in suitable proportions and ted in the shape and size desired.
The powders and tablets preferably contain from 5% or 10% to 70% of the active compound. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, , dextrin, starch, gelatin, tragacanth, methylcellulose, sodium 2012/029376 carboxymethylcellulose, a low melting wax, cocoa , and the like. The term "preparation" is intended to e the formulation of the active compound with ulating material as a carrier providing a e in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it.
Similarly, cachets and es are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms le for oral administration.
Suitable solid excipients are carbohydrate or protein fillers include, but are not d to sugars, including lactose, sucrose, mannitol, or sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose such as methyl cellulose, hydroxypropylmethyl- cellulose, or sodium carboxymethylcellulose; and gums including arabic and tragacanth; as well as proteins such as gelatin and en. If desired, disintegrating or solubilizing agents may be added, such as the cross—linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate.
Dragee cores are provided with suitable coatings such as trated sugar solutions, which may also contain gum arabic, talc, nylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound (i.e., dosage).
Pharmaceutical preparations of the invention can also be used orally using, for example, t capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating such as glycerol or sorbitol. Push—fit capsules can contain GR modulator mixed with a filler or binders such as lactose or starches, lubricants such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the GR tor compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycol with or without stabilizers.
For preparing itories, a low melting wax, such as a mixture of fatty acid glycerides or cocoa butter, is first melted and the active component is dispersed homogeneously therein, as by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.
[0079] Liquid form preparations include solutions, suspensions, and ons, for example, water or water/propylene glycol solutions. For parenteral injection, liquid preparations can be formulated in solution in aqueous hylene glycol solution.
Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, izers, and thickening agents as desired. Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active ent in water with viscous al, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum , and dispersing or wetting agents such as a naturally occurring phosphatide (e.g., lecithin), a condensation product of an alkylene oxide with a fatty acid (e. g., polyoxyethylene stearate), a condensation product of ethylene oxide with a long chain aliphatic alcohol (e.g., heptadecaethylene oxycetanol), a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol (e.g., polyoxyethylene sorbitol mono-oleate), or a condensation product of ethylene oxide with a partial ester derived from fatty acid and a hexitol anhydride (e. g., polyoxyethylene sorbitan mono—oleate). The aqueous suspension can also contain one or more preservatives such as ethyl or n—propyl p—hydroxybenzoate, one or more coloring , one or more flavoring agents and one or more sweetening agents, such as sucrose, aspartame or saccharin. Formulations can be adjusted for osmolarity.
Also included are solid form preparations, which are intended to be converted, shortly before use, to liquid form preparations for oral administration. Such liquid forms include solutions, sions, and emulsions. These preparations may contain, in on to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
Oil suspensions can be ated by suspending a GR modulator in a vegetable oil, such as arachis oil, olive oil, sesame oil or t oil, or in a mineral oil such as liquid paraffin; or a mixture of these. The oil suspensions can contain a thickening agent, such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents can be added to provide a ble oral preparation, such as glycerol, sorbitol or sucrose. These formulations can be preserved by the addition of an antioxidant such as ascorbic acid. As an example of an injectable oil vehicle, see Minto, J. Pharmacol. Exp. Ther. 281:93—102, 1997. The pharmaceutical formulations of the ion can also be in the form of oil—in-water emulsions. The oily phase can be a vegetable oil or a mineral oil, described above, or a mixture of these. Suitable emulsifying agents include naturally—occurring gums, such as gum acacia and gum tragacanth, naturally ing phosphatides, such as soybean in, esters or partial esters derived from fatty acids and hexitol anhydrides, such as an mono— oleate, and sation products of these partial esters with ethylene oxide, such as yethylene sorbitan mono—oleate. The on can also contain sweetening agents and flavoring agents, as in the formulation of syrups and elixirs. Such formulations can also contain a demulcent, a preservative, or a coloring agent.
The GR tors of the invention can be delivered by ermally, by a topical route, formulated as applicator sticks, solutions, suspensions, emulsions, gels, creams, nts, pastes, jellies, paints, powders, and aerosols.
The GR modulators and compositions of the invention can also be delivered as pheres for slow release in the body. For example, microspheres can be administered via intradermal injection of drug -containing microspheres, which slowly release subcutaneously (see Rao, J. ‘er Sci. Polym. Ed. 7:623—645, 1995; as biodegradable and injectable gel formulations (see, e.g., Gao Pharm. Res. -863, 1995); or, as microspheres for oral administration (see, e.g., Eyles, J Pharm. Pharmacol. 49:669-674, 1997). Both transdermal and intradermal routes afford constant ry for weeks or months.
[0085] The GR modulator pharmaceutical ations of the invention can be provided as a salt and can be formed with many acids, including but not limited to hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be more soluble in aqueous or other protonic solvents that are the corresponding free base forms. In other cases, the preparation may be a lyophilized powder in 1 mM-5O mM histidine, 0.1%-2% sucrose, 2%-7% mannitol at a pH range of 4.5 to 5.5, that is combined with buffer prior to use In another embodiment, the GR modulator formulations of the ion can be delivered by the use of liposomes which fuse with the ar membrane or are endocytosed, i.e., by employing ligands attached to the liposome, or attached directly to the oligonucleotide, that bind to surface membrane protein receptors of the cell ing in endocytosis. By using liposomes, particularly where the liposome surface carries ligands specific for target cells, or are otherwise preferentially directed to a specific organ, one can focus the delivery of the GR modulator into the target cells in vivo. (See, e. g., Al- Muhammed, J. Microencapsul. -306, 1996; Chonn, Curr. Opin. Biotechnol. 6:698- 708, 1995; Ostro, Am. J. Hosp. Pharm. 46:1576—1587, 1989).
[0087] The pharmaceutical preparation is preferably in unit dosage form. In such form the preparation is subdivided into unit doses containing riate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, , cachet, or lozenge , or it can be the appropriate number of any of these in packaged form.
The ty of active component in a unit dose preparation may be varied or adjusted from 0.1 mg to 10000 mg, more typically 1.0 mg to 1000 mg, most typically 10 mg to 500 mg, ing to the particular ation and the potency of the active component.
The composition can, if d, also contain other compatible therapeutic agents.
The dosage regimen also takes into consideration pharmacokinetics parameters well known in the art, i.e., the rate of absorption, bioavailability, metabolism, clearance, and the like (see, e.g., Hidalgo-Aragones (1996) J. Steroid Biochem. Mol. Biol. 58:611-617; Groning (1996) Pharmazie 51:337—341; Fotherby (1996) Contraception 54:59-69; Johnson (1995) J.
Pharm. Sci. 84:1144—1146; Rohatagi (1995) Pharmazie 50:610-613; Brophy (1983) Eur. J.
Clin. Pharmacol. 24:103-108; the latest Remington's, supra). The state of the art allows the clinician to determine the dosage regimen for each individual patient, GR modulator and disease or condition treated.
[0090] Single or multiple administrations of GR modulator formulations can be administered depending on the dosage and frequency as required and tolerated by the patient.
The formulations should provide a sufficient quantity of active agent to effectively treat the disease state. Thus, in one embodiment, the pharmaceutical formulations for oral administration of GR modulator is in a daily amount of between about 0.5 to about 20 mg per kilogram of body weight per day. In an alternative embodiment, dosages are from about 1 mg to about 4 mg per kg of body weight per patient per day are used. Lower dosages can be used, ularly when the drug is administered to an anatomically secluded site, such as the cerebral spinal fluid (CSF) space, in contrast to stration orally, into the blood stream, into a body cavity or into a lumen of an organ. Substantially higher dosages can be used in topical administration. Actual methods for preparing parenterally strable GR modulator formulations will be known or apparent to those skilled in the art and are described in more detail in such publications as Remington's, supra. See also Nieman, In "Receptor Mediated Antisteroid Action," Agarwal, et al., eds., De Gruyter, New York (1987).
The compounds described herein can be used in combination with one another, with other active agents known to be useful in modulating a glucocorticoid receptor, or with adjunctive agents that may not be effective alone, but may bute to the efficacy of the active agent.
In some embodiments, inistration includes administering one active agent within 0.5, 1, 2, 4, 6, 8, 10, 12, 16, 20, or 24 hours ofa second active agent. Co- administration includes stering two active agents simultaneously, approximately simultaneously (e.g., within about 1, 5, 10, 15, 20, or 30 minutes of each other), or sequentially in any order. In some embodiments, co—administration can be accomplished by co-formulation, i.e., preparing a single pharmaceutical composition ing both active agents. In other ments, the active agents can be formulated separately. In another embodiment, the active and/or adjunctive agents may be linked or conjugated to one r.
After a pharmaceutical ition including a GR modulator of the invention has been formulated in an acceptable carrier, it can be placed in an appropriate ner and labeled for treatment of an indicated condition. For administration of GR modulators, such labeling would include, e. g., instructions concerning the amount, frequency and method of stration.
The pharmaceutical compositions of the present invention can be provided as a salt and can be formed with many acids, ing but not limited to hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be more soluble in aqueous or other protonic solvents that are the corresponding free base forms. In other cases, the preparation may be a lyophilized powder in 1 mM-50 mM histidine, 0.1%—2% sucrose, 2%—7% mannitol at a pH range of 4.5 to 5.5, that is combined with buffer prior to use.
[0095] In another embodiment, the compositions of the present invention are useful for parenteral administration, such as intravenous (IV) administration or administration into a body cavity or lumen of an organ. The formulations for administration will ly comprise a on of the compositions of the t invention dissolved in a pharmaceutically acceptable carrier. Among the acceptable vehicles and solvents that can be employed are water and Ringer’s solution, an isotonic sodium chloride. In addition, sterile fixed oils can tionally be ed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono~ or diglycerides. In addition, fatty acids such as oleic acid can likewise be used in the preparation of injectables.
These solutions are sterile and generally free of undesirable matter. These formulations may be sterilized by conventional, well known sterilization techniques. The formulations may contain pharmaceutically acceptable ary substances as required to imate physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents, e.g., sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate and the like. The concentration of the compositions of the present invention in these formulations can vary widely, and will be selected primarily based on fluid volumes, viscosities, body weight, and the like, in accordance with the particular mode of administration selected and the patient's needs. For IV administration, the formulation can be a sterile injectable preparation, such as a sterile inj ectable aqueous or oleaginous suspension.
This suspension can be formulated according to the known art using those suitable sing or wetting agents and suspending agents. The sterile injectable preparation can also be a sterile inj ectable solution or suspension in a nontoxic parenterally—acceptable diluent or solvent, such as a solution of 1,3—butanediol.
In another embodiment, the formulations of the compositions of the present ion can be delivered by the use of liposomes which fuse with the cellular membrane or are endocytosed, i.e., by ing ligands attached to the liposome, or attached directly to the oligonucleotide, that bind to surface membrane protein receptors of the cell resulting in endocytosis. By using mes, particularly where the liposome surface carries ligands c for target cells, or are ise preferentially directed to a specific organ, one can focus the delivery of the compositions of the present invention into the target cells in vivo.
(See, e.g., Al—Muhammed, J Microencapsul. 13:293-306, 1996; Chonn, Curr. Opin.
Biotechnol. 6:698—708, 1995; Ostro,Am. J. Hosp. Pharm. 46:1576-1587, 1989).
V. Method of Treating via Glucocorticoid tion In some embodiments, the present invention provides a method of treating a disorder or condition through modulating a glucocorticoid receptor, the method including administering to a subject in need of such treatment, a therapeutically effective amount of a nd of formula I.
In some other ments, the present invention provides a method of ng a disorder or condition through antagonizing a orticoid or, the method including administering to a subject in need of such treatment, an effective amount of the compound of formula I.
In another embodiment, the present invention provides methods of modulating glucocorticoid receptor activity using the techniques described herein. In an exemplary embodiment, the method includes ting a GR with an effective amount of a nd of the present invention, such as the compound of formula I, and detecting a change in GR activity.
WO 29074 In an exemplary embodiment, the GR modulator is an antagonist of GR activity (also referred to herein as "a glucocorticoid receptor antagonist"). A glucocorticoid receptor antagonist, as used herein, refers to any composition or compound which partially or completely inhibits (antagonizes) the binding of a glucocorticoid receptor (GR) agonist (e.g. cortisol and synthetic or natural cortisol analog) to a GR thereby inhibiting any biological se associated with the binding of a GR to the agonist.
In a related embodiment, the GR modulator is a specific glucocorticoid receptor antagonist. As used herein, a specific glucocorticoid receptor nist refers to a composition or compound which inhibits any biological se associated with the binding of a GR to an agonist by preferentially binding to the GR rather than another r receptor (NR). In some embodiments, the specific orticoid receptor antagonist binds preferentially to GR rather than the mineralocorticoid or (MR) or progesterone receptor (PR). In an exemplary embodiment, the specific glucocorticoid receptor antagonist binds preferentially to GR rather than the mineralocorticoid receptor (MR). In another exemplary embodiment, the specific glucocorticoid receptor antagonist binds preferentially to GR rather than the progesterone receptor (PR).
In a related embodiment, the specific glucocorticoid receptor nist binds to the GR with an association constant (Kd) that is at least 10-fold less than the Kd for the NR. In another embodiment, the specific glucocorticoid receptor antagonist binds to the GR with an 2O association constant (Kd) that is at least lOO-fold less than the Kd for the NR. In another ment, the specific glucocorticoid or antagonist binds to the GR with an association constant (Kd) that is at least IOOO—fold less than the Kd for the NR.
Examples of disorders or conditions suitable for use with present invention include, but are not limited to, y, diabetes, cardiovascular disease, hypertension, Syndrome X, depression, anxiety, glaucoma, human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS), neurodegeneration, mer's disease, Parkinson's disease, cognition enhancement, Cushing's Syndrome, Addison's Disease, osteoporosis, frailty, muscle frailty, inflammatory diseases, osteoarthritis, rheumatoid arthritis, asthma and rhinitis, adrenal function—related ailments, viral infection, deficiency, immunomodulation, autoimmune diseases, allergies, wound g, compulsive behavior, drug ance, addiction, psychosis, anorexia, cachexia, raumatic stress syndrome, post—surgical bone fracture, l catabolism, major tic depression, mild ive impairment, psychosis, dementia, hyperglycemia, stress disorders, antipsychotic induced weight gain, delirium, cognitive impairment in depressed patients, cognitive deterioration in individuals with Down's syndrome, psychosis associated with interferon- alpha therapy, chronic pain, pain associated with gastroesophageal reflux disease, postpartum psychosis, postpartum depression, neurological ers in premature infants, and migraine headaches. In some embodiments, the disorder or condition is major psychotic depression, stress disorders or antipsychotic induced weight gain.
VI. Assays and Methods for Modulating Glucocorticoid or Activity The compounds of the present invention can be tested for their ucocorticoid properties. s of assaying compounds capable of ting glucocorticoid receptor activity are presented . Typically, compounds of the t invention are capable of modulating glucocorticoid receptor activity by selectively binding to the GR or by preventing GR ligands from binding to the GR. In some ments, the compounds exhibit little or no cytotoxic effect.
A. g Assays In some embodiments, GR modulators are identified by screening for molecules that compete with a ligand of GR, such as dexamethasone. Those of skill in the art will recognize that there are a number of ways to perform competitive binding assays. In some embodiments, GR is pre—incubated with a labeled GR ligand and then contacted with a test compound. This type of competitive g assay may also be referred to herein as a binding displacement assay. Alteration (e.g., a decrease) of the quantity of ligand bound to GR indicates that the molecule is a potential GR modulator. Alternatively, the binding of a test compound to GR can be measured ly with a labeled test compound. This latter type of assay is called a direct binding assay.
Both direct binding assays and competitive g assays can be used in a variety of different s. The formats may be similar to those used in immunoassays and receptor binding assays. For a description of different formats for binding assays, ing competitive binding assays and direct binding assays, see Basic and Clinical Immunology 7th Edition (D. Stites and A. Terr ed.) 1991; Enzyme Immunoassay, E.T. Maggio, ed., CRC Press, Boca Raton, Florida (1980); and "Practice and Theory of Enzyme assays," P.
Tijssen, Laboratory Techniques in Biochemistry and Molecular Biology, Elsevier Science Publishers B.V. Amsterdam (1985), each of which is incorporated herein by reference.
In solid phase competitive binding assays, for example, the sample compound can compete with a labeled analyte for specific binding sites on a binding agent bound to a solid surface. In this type of format, the labeled e can be a GR ligand and the binding agent can be GR bound to a solid phase. atively, the labeled e can be labeled GR and the g agent can be a solid phase GR . The concentration of labeled analyte bound to the capture agent is inversely proportional to the ability of a test compound to compete in the binding assay.
Alternatively, the competitive binding assay may be conducted in liquid phase, and any of a variety of techniques known in the art may be used to separate the bound labeled n from the unbound labeled protein. For example, several procedures have been developed for distinguishing between bound ligand and excess bound ligand or between bound test compound and the excess unbound test compound. These include identification of the bound complex by sedimentation in sucrose gradients, gel electrophoresis, or gel isoelectric focusing; precipitation of the receptor—ligand complex with protamine sulfate or adsorption on hydroxylapatite; and the removal of unbound compounds or ligands by adsorption on dextran—coated charcoal (DCC) or binding to immobilized antibody. Following tion, the amount of bound ligand or test compound is determined.
Alternatively, a homogenous binding assay may be performed in which a separation step is not needed. For example, a label on the GR may be altered by the binding'of the GR 2O to its ligand or test compound. This alteration in the d GR results in a decrease or increase in the signal emitted by label, so that measurement of the label at the end of the binding assay allows for detection or quantitation of the GR in the bound state. A wide variety of labels may be used. The component may be labeled by any one of several methods. Useful radioactive labels include those incorporating 3H, 125I, 358, 14C, or 32F.
Useful non—radioactive labels include those incorporating fluorophores, chemiluminescent agents, phosphorescent agents, electrochemiluminescent agents, and the like. Fluorescent agents are especially useful in analytical techniques that are used to detect shifts in protein structure such as cence ropy and/or fluorescence polarization. The choice of label s on sensitivity required, ease of conjugation with the compound, stability ements, and available instrumentation. For a review of various labeling or signal producing s which may be used, see US. Patent No. 4,391,904, which is incorporated herein by reference in its entirety for all purposes. The label may be coupled directly or indirectly to the desired component of the assay ing to methods well known in the art.
High-throughput screening methods may be used to assay a large number of potential tor nds. Such "compound libraries" are then screened in one or more assays, as bed herein, to identify those library members cular chemical species or subclasses) that [display a desired characteristic activity. Preparation and screening of chemical libraries is well known to those of skill in the art. Devices for the preparation of chemical libraries are commercially available (see, e.g., 357 MPS, 390 MPS, Advanced Chem Tech, Louisville KY, Symphony, Rainin, Wobum, MA, 433A d Biosystems, Foster City, CA, 9050 Plus, Millipore, Bedford, MA).
B. Cell-Based Assays
[0111] Cell-based assays involve whole cells or cell fractions containing GR to assay for binding or modulation of activity of GR by a compound of the present invention. Exemplary cell types that can be used according to the methods of the invention include, e.g., any mammalian cells including leukocytes such as neutrophils, monocytes, hages, eosinophils, basophils, mast cells, and lymphocytes, such as T cells and B cells, leukemias, t's lymphomas, tumor cells (including mouse y tumor virus cells), endothelial cells, asts, cardiac cells, muscle cells, breast tumor cells, ovarian cancer carcinomas, al carcinomas, glioblastomas, liver cells, kidney cells, and neuronal cells, as well as fungal cells, ing yeast. Cells can be primary cells or tumor cells or other types of immortal cell lines. Of course, GR can be expressed in cells that do not express an endogenous version of GR.
In some cases, fragments of GR, as well as protein fusions, can be used for ing. When molecules that compete for binding with GR ligands are desired, the GR fragments used are fragments capable of binding the ligands (e.g., dexamethasone).
Alternatively, any fragment of GR can be used as a target to fy molecules that bind GR.
GR fragments can include any fragment of, e.g., at least 20, 30, 40, 50 amino acids up to a protein containing all but one amino acid of GR. Typically, ligand—binding fragments will comprise transmembrane regions and/or most or all of the extracellular domains of GR.
In some embodiments, signaling triggered by GR activation is used to identify GR modulators. Signaling activity of GR can be determined in many ways. For example, downstream molecular events can be red to determine signaling activity. Downstream events include those activities or manifestations that occur as a result of stimulation of a GR receptor. Exemplary downstream events useful in the onal evaluation of transcriptional activation and antagonism in unaltered cells include upregulation of a number of glucocorticoid response element (GRE)—dependent genes (PEPCK, tyrosine amino erase, aromatase). In addition, specific cell types susceptible to GR activation may be used, such as osteocalcin expression in osteoblasts which is downregulated by glucocorticoids; y hepatocytes which exhibit glucocorticoid mediated upregulation of PEPCK and e-6—phospahte (GPase)). GRE-mediated gene expression has also been demonstrated in transfected cell lines using well—known GRE—regulated sequences (e. g. the mouse mammary tumor virus promoter (MMTV) transfected upstream of a reporter gene construct). Examples of useful reporter gene constructs include luciferase (luc), alkaline phosphatase (ALP) and chloramphenicol acetyl transferase (CAT). The functional evaluation of transcriptional repression can be carried out in cell lines such as monocytes or human skin fibroblasts. Useful functional assays include those that measure IL-lbeta stimulated IL-6 expression; the downregulation of collagenase, cyclooxygenase-2 and various ines (MCP-l , RANTES); or expression of genes regulated by NFkB or AP—l transcription factors in transfected ines.
[0114] Typically, compounds that are tested in whole—cell assays are also tested in a xicity assay. Cytotoxicity assays are used to ine the extent to which a perceived modulating effect is due to non-GR binding cellular effects. In an exemplary embodiment, the cytotoxicity assay includes contacting a constitutively active cell with the test compound.
Any decrease in cellular activity tes a cytotoxic effect.
C. Specificity The compounds of the t invention may be subject to a specificity assay (also referred to herein as a selectivity assay). Typically, specificity assays include testing a compound that binds GR in vitro or in a cell—based assay for the degree of binding to non-GR proteins. Selectivity assays may be performed in vitro or in cell based systems, as described above. GR binding may be tested t any appropriate non-GR protein, including dies, receptors, enzymes, and the like. In an exemplary embodiment, the non-GR binding n is a cell—surface or or nuclear receptor. In another exemplary embodiment, the non—GR n is a steroid receptor, such as estrogen receptor, progesterone receptor, androgen receptor, or mineralocorticoid receptor.
[0116] The terms and expressions which have been employed herein are used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding equivalents of the features shown and described, or portions thereof, it being recognized that s ations are possible within the scope of the invention claimed. Moreover, any one or more features of any embodiment ofthe invention may be combined with any one or more other features of any other ment of the ion, without departing from the scope of the invention. For e, the features of the GR modulator compounds are equally applicable to the methods of treating disease states and/or the pharmaceutical compositions described herein. All publications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety for all VII. Examples LCMS methods:
[0118] Method A: experiments were med using a Waters Platform LC quadrupole mass spectrometer with positive and negative ion electrospray and ELS / Diode array detection using a Phenomenex Luna 3 micron C18 (2) 30 x 4.6 mm column and a 2 mL/ minute flow rate. The solvent system was a 95% water containing 0.1% formic acid (solvent A) and a 5% acetonitrile containing 0.1% formic acid nt B) for the first 50 seconds followed by a gradient up to 5% solvent A and 95% solvent B over the next 4 s. The final solvent system was held constant for a further 1 .
Method B: experiments were performed using a Waters Micromass ZQ2000 quadrupole mass spectrometer with a ve and negative ion electrospray and ELS / Diode array detection using a Higgins Clipeus 5 micron C18 100 x 3.0 mm column and a 1 mL/ minute flow rate. The initial solvent system was 95% water containing 0.1% formic acid (solvent A) and a 5% acetonitrile containing 0.1% formic acid (solvent B) for the first minute followed by a gradient up to 5% solvent A and 95% solvent B over the next 8 minutes. The final solvent system was held constant for a further 5 minutes.
Method C: ments were performed using a Waters ZMD quadrupole mass spectrometer with positive and negative ion electrospray and ELS / Diode array detection using a Phenomenex Luna 3 micron C18 (2) 30 x 4.6 mm column and a 2 mL / minute flow rate. The solvent system was a 95% water containing 0.1% formic acid (solvent A) and a 5% acetonitrile containing 0.1% formic acid (solvent B) for the first 50 seconds ed by a gradient up to 5% solvent A and 95% solvent B over the next 4 minutes. The final t system was held constant for a further 1 minute.
Method D: experiments were performed using a Waters Micromass ZQ2000 quadrupole mass spectrometer linked to a Waters Acquity UPLC system with a PDA UV detector using an Acquity UPLC BEH C18 1.7micron 100X2.1mm, maintained at 40°C. The spectrometer has an electrospray source operating in ve and negative ion mode. The initial solvent system was 95% water containing 0.1% formic acid (solvent A) and a 5% acetonitrile containing 0.1% formic acid nt B) for 0.4 s followed by a gradient up to 5% solvent A and 95% solvent B over the next 6.4 minutes.
Method B: experiments were med using a Waters Quattro Micro triple quadrupole mass spectrometer linked to a Hewlett Packard HP1100 LC system with a positive and negative ion electrospray and ELS / Diode array detection using a Higgins Clipeus 5 micron C18 100 x 3.0 mm column and a 1‘mL/ minute flow rate. The initial solvent system was 85% water ning 0.1% formic acid (solvent A) and 15% acetonitrile containing 0.1% formic acid (solvent B) for the first minute ed by a gradient up to 5% solvent A and 95% solvent B over the next 13 minutes. The solvent system was held constant for a further 7 minutes before returning to the initial solvent conditions.
Exam le 1: Pre aration of S-Ben l—6— 4— hen 1c clohex—l—en l-lH- rimidine—Z 4- dione (2a! CF3SOZO Trifluoromethanesulfonic acid 4—phenyl—cyclohex—1-enyl ester. A solution of diisopropylamine (4.46 mL) in tetrahydrofuran (25 mL) under nitrogen at -20 °C was treated with a 2.5 M solution of n-butyl lithium (12.6 mL) and stirred for 15 minutes. The resulting mixture was cooled to —78 °C before a solution of 4—phenylcyclohexanone (5.0 g) in ydrofuran (20 mL) was added over 20 minutes. The resulting solution was d at —78 °C for 3 hours then treated with a solution of N—phenyl-bis(trifluoromethanesulfonimide) (10.76 g) in tetrahydrofuran (25 mL). The mixture was stirred at —78 °C for 1.5 hours then warmed to room temperature and stirred for a r 18 hours. The reaction mixture was concentrated under reduced pressure and the resulting residue partitioned between ethyl acetate and water. The organic layer was washed with 2M sodium hydroxide solution and brine, then dried over sodium sulfate. The solvent was removed under reduced pressure to afford the title compound as an oil (7.3 g). 1H NMR (CDC13): 5 7.32—7.31 (2 H, m), 7.24—7.22 (3 H, m), .84 (1 H, m), 2.85—2.84 (1 H, m), .54 (1 H, m), 2.44-2.43 (2 H, m), 2.35-2.34 (1 H, m), 2.09—2.07 (1 H, m), 1.96-1.95 (1 H, m). 853‘ 4,4,5,5~Tetramethyl—2—(4—phenylcyclohex—1—enyl)—[1,3,2]dioxaborolane. A mixture of trifluoro-methanesulfonic acid 4-phenyl-cyclohexenyl ester (5.8 g), bis(pinacolato)diboron (5.3 g), potassium acetate (5.58 g) and [1,1 ’- bis(diphenylphosphine)fe1rocene]dichloropalladium(II) (0.77 g) in 1,4-dioxane (150 mL) was ed then heated to 80 0C for 2 hours. The reaction mixture was filtered and the resulting filtrate concentrated under reduced pressure. The resulting residue was d by column chromatography on silica gel, eluting with a e of diethyl ether and cyclohexane (0:1 to 1:20 by volume) to afford the title compound (4.0 g). 1H NMR(CDC13): 8 7.30—7.28 (2 H, m), 7.24-7.15 (3 H, m), 6.65—6.64 (1 H, m), 2.82-2.71 (1 H, m), 2.40-2.36 (2 H, m), 2.23—2.22 (2 H, m), .94 (1 H, m), 1.70—1.68 (1 H, m), 1.43 (3 H, s), 1.28 (9 H, s). 5-Benzyl—6—(4—phenylcyclohex-1—enyl)—1H-pyrimidine—2,4—dione (2a). A mixture of yl—6-chloro-lH-pyrimidine—2,4—dione (WOO6014394) (1.0 g), 4,4,5,5—tetramethyl—2—(4— phenylcyclohex—l~enyl)—[1,3,2]dioxaborolane (1.4 g), bis[di-tert-butyl(4— dimethylaminophenyl)phosphine]dichloropalladium(II) (0.06 g) and cesium fluoride (1.92 g) in 1,4—dioxane (18 mL) and water (2 mL) was heated at 140 °C in a microwave reactor for 20 minutes. The resulting mixture was diluted with saturated aqueous ammonium de and filtered to remove the precipitate. The filtrate was extracted with dichloromethane and the combined organic layers washed with water and brine, then dried over sodium sulfate and concentrated under reduced pressure. The resulting residue was purified by column chromatography on silica gel, g with a mixture of methanol and dichloromethane (0:1 to 1:20 by ) to afford the title compound 2a as an off-white solid (0.48 g). LCMS (Method A): R = 3.56 min. (M+H)+= 359. 1H NMR (DMSO-D6): 8 11.06 (1 H, s), 10.69 (1 H, s), 7.23-7.21 (10 H, m), 5.84-5.79 (1 H, m), 3.61 (2 H, s), 3.57 (1 H, s), .67 (1 H, m), 2.19-2.16 (3 H, m), 1.84-1.81 (1 H, m), 1.68-1.67 (1 H, m).
Exam les 2-4: Pre aration 0f 5-Substituted 6- 4-Phen lc clohex-l—en 1 -1H- pyrimidine-2,4-di0nes The intermediates shown in Table 1 were prepared following the procedures described in W0060143 94, the contents of which are herein incorporated by reference in their entirety.
Table 1: Previous] bed chloro rimidinedione intermediates. ediate Structure 1H NMR / 8 o (DMSO-dé): 12.00 (1 H, 5), 11.42 (1 H, 5), 1a 7.16-7.14 (1 H, m), .07 (2 H, m), 6.92- :5: | 6.87 (1 H, m), 3.59 (2 H, s), 2.31 (3 H, s). o N CI 0 CI (DMSO—dé): 12.07 (1 H, 5), 11.46 (1 H, s), 1b 744—743 (1 H, m), 725-724 (2 H, m), 7.11- 1 7.10 (1 H, m), 3.72 (2 H, s). o N c1 o (DMSO-dé): 11.95 (1 H, 5), 11.38 (1 H, 5), 1c 7.14 (1 H, t, .1 = 7.46 Hz), 7.02—6.95 (3 H, m), 1 3.61 (2 H, s), 2.26 (3 H, s). o N c1 The examples shown in Table 2 were prepared using similar methods to those described for Example 1, using intermediates la—1c in Table 1 in the final cross coupling.
Table 2: 5—Substituted 6- 4- hen 1c clohex-l—en l-lH- ne-2 4—di0nes re ared via alladium—catal zed cross cou lin .
Example Compound Structure IH NMR / 8 LCMS O (DMSO~d6): 11.06 (1 H, 5), 10.68 (1 H, s), 7.26-7.25 (5 H, m), 7.13 (1 H, A I t, .1 = 7.78 Hz), 6.94-6.93 (3 H, m), (Method B) 0 n ‘ 5.85-5.79 (1 H, m), 3.57 (2 H, 5), RI = 5.13 min 2 2b 2.76-2.65 (1 H, m), 2.37-2.28 (1 H, (M+H)+ = O m), 2.26 (3 H, s), 2.23—2.09 (2 H, 373 m), 2.04-2.00 (1 H, m), 1.87—1.76 (1 ethy1~benzyl)-6—(4-phenyl- H, m), 1.67—1.65 (1 H, m). cyclohex—l —enyl)—l H—pyrimidine— 2,4—dione 2012/029376 (DMSO~d6): 11.14 (1 H, 5), 10.77 (1 H, s), 7.42—7.41 (1 H, m), 7.24—7.22 (7 H, m), .09 (1 H, m), 5.81- gMzeghfgggn 3 2c 5.75 (1 H, m), 3.67 (2 H, s), 2.71— ‘(MJeH)+= 2.59 (1 H, m), 2.15—2.11 (4 H, m), 1.82-1.73 (1 H, m), 1.59-1.58 (1 H, —(2~Chloro-benzyl)(4-phenyl- cyclohex—l—enyl)—1H-pyrimidine— 2,4-dione (DMSO—dé): 11.08 (1 H, 5), 10.70 (1 H, s), 7.31—7.23 (2 H, m), 7.20—7.04 (6 H, m), 6.90-6.89 (1 H, m), 5.82- (Method B) 4 2d 5.76 (1 H, m), 3.53 (2 H, s), 2.69- Rt = 5.05 min 2.59 (1 H, m), 2.26 (3 H, s), 2.24- (M+H)+= 373 1.94 (4 H, m), 1.81-1.70 (1 H, m), 1'58'1'57 (1 H” m). -(2-Methyl—benzyl)—6-(4—phenyl— cyclohex—l-enyl)-1H-pyrimidine- 2,4-dione Exam le 5: Pre n of E Benz l 4- hen 1c clohex l-lH- rimidine-Z 4- dione 13a) (E)Benzyl(4-phenylcyclohexyl)—1H-pyrimidine—2,4~dione (3a). A solution of ~benzyl—6—(4—phenylcyclohexenyl)—1H—pyrimidine-2,4—dione (2a) (380mg) in a [5:2] mixture of IMS/DCM was hydrogenated over Pd(OH)2 (150 mg) and 10% Pd/C (100 mg) at 45 psi at 50 °C for 18 hours. The crude reaction mixture was degassed with Argon, filtered h a Celite pad and concentrated in vacuuo to give a cream solid. 1H NMR showed a mixture of cis/trans isomers, a portion of which was ted into individual isomers using a C18 Synergy column eluting with 70—80% MeOH/water (+0.1% formic acid) over 20 minutes, then isocratic (80%) for a further 5 minutes. 1H NMR hexane bridgehead protons coupling constants) allowed assignment of the first eluting isomer as the trans isomer 3a and the second as the cis isomer 3bb. First—eluting isomer 3a: R = 10.86 min, (M+H)+ = 361. Second—eluting cis isomer 3bb: R = 11.01 min, (M+H)+ = 361.
Exam le 6: Pre aration of E 4-Phen lc clohex l 3-trifluorometh lben l—lH- pyrimidine—2,4—dione‘ (3b) Phenylcyclohexanecarboxylic acid (5). A mixture of (E)—4—(4-chlorophenyl)- cyclohexanecarboxylic acid (4) (15 g) and 10% palladium on carbon (4 g) in l (400 mL) was stirred under an atmosphere of hydrogen for 4 days. The reaction mixture was diluted with dichloromethane, filtered through Celite® and the e concentrated under reduced pressure. The resulting residue was dissolved in ethanol (150 mL) and d with 5 M aqueous sodium hydroxide (25 mL). The resulting mixture was d at room temperature for 16 hours then concentrated under d pressure. The residue was treated with 1 M with ethyl aqueous hydrochloric acid (200 mL) and stirred for 15 minutes then extracted e. The combined organic phases were dried over sodium sulfate and concentrated under reduced re to afford the title compound as a white solid (11 g). 1H NMR(CDC13): 8 7.27-7.25 (5 H, m), 2.52 (1 H, tt, J = 11.90, 3.44 Hz), 2.48-2.29 (1 H, m), 2.17-2.14 (2 H, m), 2.02—1.98 (2 H, m), .55 (4 H, m). 0 O (E)—3-Oxo(4—phenylcyclohexyl)—propionic acid ethyl ester (7). A mixture of (E)— 4-phenylcyclohexanecarboxylic acid (5) (11 g), dimethylpyridin—4-yl-amine (7.3 g), 2,2— dimethyl—[l,3]dioxane—4,6—dione (8.5 g) and 4 A molecular sieves (2.0 g) in dichloromethane (200 mL) was stirred at room temperature for 10 minutes then treated with a solution of dicyclohexylcarbodiimide (12.4 g) in dichloromethane (40 mL). The resulting mixture was stirred at room temperature for 1.5 hours then filtered and the filtrate washed with 1 M under aqueous hydrochloric acid and water, then dried over sodium sulfate and concentrated reduced pressure. The resulting solid was dissolved in ethanol (100 mL) and heated at reflux for 1.5 hours then concentrated under reduced pressure. The resulting residue was purified by column chromatography on silica gel, eluting with a mixture of ethyl e and cyclohexane (0:1 to 3:7 by volume) to afford the title compound as a white solid (11 g). 1H NMR (CDC13)Z 8 7.23—7.22 (5 H, m), 4.25-4.17 (2 H, m), 3.52 (2 H, s), 2.54-2.53 (2 H, m), 2.09-1.99 (4 H, m), 1.54-1.51 (4 H, m), 1.32-1.25 (3 H, m). "’1, : (Z)—2-(4—Phenylcyclohexanecarbonyl)-3—(3—trifluoromethylphenyl)—acrylic acid ethyl ester (10). 3-Oxo—3—(4-phenyl-cyclohexyl)—propionic acid ethyl ester (7) (11.56 g, 42.1 mmol), 3-trifluoromethylbenzaldehyde (11g, 63.15 mmol), glacial acetic acid (7.16 mmol, 0.41 mL) and piperidine (2.1 mmol, 0.21 mL) were dissolved in toluene (250 mL) and heated under Dean and Stark conditions at reflux for 48 hours. The cooled reaction mixture was diluted with an equal volume of ethyl acetate and washed with 1M aq. HCl and brine. The organics were dried over sodium sulfate, filtered, and evaporated to afford a clear, brown oil.
The residue was purified by column tography on silica gel ent: 0 to 10% tert- butyl methyl ether in cyclohexane) to afford 12.3 g (68%) of (Z)—2-(4—phenyl- cyclohexanecarbonyl)(3-trifluoromethyl-phenyl)~acrylic acid ethyl ester. 1H NMR (400 MHz, 192191), LCMS (method C), R = 4.77 min, (M+H)+ = 431.2. 0 0 3—Oxo—3—(4—phenylcyclohexyl)—2-(3-trifluoromethylbenzyl)-propionic acid ethyl ester (1 1). A mixture of (Z)—2—(4—phenylcyclohexanecarbonyl)—3—(3-trifluoromethylphenyl)— acrylic acid ethyl ester (10) (12.3 g, 28.6 mmol) and 10% Pd on carbon (2.5 g, 20% by weight) in denatured l (250 mL) was stirred under a hydrogen atmosphere for 2 hr. The solids were removed by filtration through celite and washed with ethanol. The filtrate was ated under vacuum to yield a clear oil. The residue was purified by column chromatography on silica gel (gradient: 0 to 10% tert-butyl methyl ether in cyclohexane) to afford 8.6g (70%) of 3—oxo-3—(4—phenylcyclohexyl)(3—trifluoromethylbenzyl)—propionic acid ethyl ester (22). 1H NMR (400 MHz, 192227). LCMS (method A), R = 4.76 min, (M+H)+ = 433.2 (94%); R = 5.22 min, (M+H)Jr = 262.9 (6.5%).
(E)—6—(4-Phenylcyclohexyl)—2—thioxo(3—trifluoromethylbenzyl)-2,3 -dihydro-1H- pyrimidin—4—one (12a). Sodium (5g, 217.8 mmol) and thiourea (18g, 236 mmol) were dissolved in absolute ethanol (300 mL) and heated at reflux under nitrogen for 1 hr. The reaction mixture was cooled to 0°C and 3-oxo—3-(4—phenylcyclohexyl)(3- trifluoromethylbenzyl)-propionic acid ethyl ester (11) , 36.3 mmol) in absolute ethanol (150 mL) was added slowly (reaction mixture temperature <10°C). The on mixture was heated at reflux for 1.5 hr. The reaction mixture was cooled then evaporated under vacuum to a peach-colored solid. The solid was suspended in water (500 mL) and adjusted to pH = 5 with glacial acetic acid. The resulting precipitate was isolated by filtration, re—dissolved in DCM, and passed through a phase separation cartridge to remove water. The filtrate was evaporated to an off-white solid that was triturated in hot methanol. The solid was recovered by ion and dried under vacuum at 50°C to afford 4.8g (30%) of the title compound. 1H NMR (400 MHz, 192268). LCMS (method C): R = 4.10 min, (M+H)+ = 444.9.
(E)-6—(4-Phenylcyclohexyl)(3—trifluoromethylbenzyl)—1H—pyrimidine—2,4-dione (3 b). (E)—6-(4-Phenylcyclohexyl)-2—thioxo-5—(3 oromethylbenzyl)—2,3 -dihydro— 1 H— pyrimidineone (12a) (4.8g, 10.8 mmol) was suspended in dioxane (150 mL), and 10% (w/v) aqueous chloroacetic acid (100 mL) was added. The reaction mixture was heated at 100°C, and further dioxane (25 mL) was added to effect complete dissolution. Heating was continued for 64 hr. The cooled reaction mixture was d with water and extracted with romethane. The combined organics were washed with saturated aqueous sodium carbonate and brine, dried over sodium sulfate, filtered, and ated to yield an off—white solid that was triturated in hot methanol. The solid was recovered by filtration and dried under vacuum at 50°C to afford 3.7 g (80%) of the title compound. 1H NMR (DMSO‘dé): 8 11.12 (1 H, s), 10.52 (1 H, s), 7.61 (1 H, s), 7.51 (3 H, m), 730-713 (5 H, m), 3.83 (2H, s), 2.90 (1 H, m), 1.83-1.80 (4 H, m), .40 (4 H, m). LCMS (method B): 11,: 5.26 min, (M+H)+ = 429.01.
Exam le 7: Pre aration of E pyrimidine-2,4-dione 13h) 7,], :: (2-Ethylbenzyl)—3—oxo—3—(4~phenylcyclohexyl)—propionic acid ethyl ester (1 1a). A suspension of sodium hydride (0.07 g) in tetrahydrofuran (10 mL) was d with a solution of (E)—3-oxo(4-phenylcyclohexyl)-propionic acid ethyl ester (7) (0.50 g) in tetrahydrofuran (8 mL), and the resulting e stirred for 1 hour at room temperature. 1— Bromomethylethylbenzene (0.38 g) was added and the resulting mixture was refluxed for 2 hours, cooled to room temperature, and quenched by addition of 1 M aqueous hydrochloric acid. The aqueous phase was extracted with ethyl acetate and the combined organic phases were washed with brine, dried over magnesium sulfate, and concentrated under reduced pressure. The resulting residue was purified by column chromatography on silica gel eluting with a mixture of dichloromethane and cyclohexane (0:1 to 4:6 by volume) to afford the title compound (0.86 g). 1H NMR (CDC13): 8 7.31-7.27 (1 H, m), 7.17-7.16 (6 H, m), 7.09-7.08 (2 H, m), 4.16—4.16 (2 H, m), 3.97 (1 H, t, J = 7.47 Hz), 3.22—3.21 (2 H, m), 2.68 (2 H, q, J = 7.55 Hz), 2.41-2.41 (2 H, m), 1.94-1.92 (3 H, m), 1.75-1.68 (1 H, m), 1.54 (1 H, s), 1.40-1.39 (3 H, m), 1.27-1.18 (6 H, m). 0 1 (3~Methylbenzyl)oxo(4-phenylcyclohexyl)-propionic acid ethyl ester (11h). The title compound was prepared as described for compound 11a above. 1H NMR (CDCl3)I 7.29 (2 H, m), 7.17-7.12 (4 H, m), 7.02-6.95 (3 H, m), 4.16 (2 H, qd, J = 7.13, 2.38 Hz), 3.95 (1 H, t, J = 7.51 Hz), 3.13 (2 H, dd, J = 7.52, 2.32 Hz), 2.45 (2 H, m), 2.31 (3 H, s), 1.97—1.94 (3 H, m), 1.80—1.73 (1 H, m), 1.53—1.27 (4 H, m), 1.22 (3 H, t, J = 7.13 Hz).
(E)—6-(4-Phenylcyclohexyl)thioxo—5-(3—methylbenzyl)~2,3~dihydro—1H— dinone (12g). The title compound was prepared from compound 11h as described for compound 12a above. LCMS (method A): R = 4.07 min, (M+H)Jr = 391.
(E)~5—(3—Methylbenzyl)—6-(4-phenylcyclohexyl)—1H-pyrimidine—2,4—dione (3h).
The title nd was prepared from compound 12g as described for compound 3b above. 1H NMR (DMSO—d6): 11.06 (1 H, s), 10.46 (1 H, s), 7.32—7.24 (2 H, m), 7.18-7.16 (4 H, m), 7.00—6.98 (3 H, m), 3.68 (2 H, s), 2.90-2.79 (1 H, m), 2.48—2.44 (1 H, m), 2.25 (3 H, s), 1.91— 1.73 (4 H, m), 1.46-1.43 (4 H, m). LCMS (method B), R = 5.17 min, (M+H)Jr = 375.
Exam les 8-34: Pre aration 0f S-Substituted E 4—c clohex l-1H- rimidine-Z 4- diones Intermediates 11 in Table 3 below were prepared from 7b as described for compound 11a in e 7.
Table 3: 2-Substituted E 0x0-3— 4- hen lc clohex 1- r0 ionic acid eth lesters.
Intermediate Structure 1H NMR / 6 o o (CDC13): 7.30-7.15 (10 H. m), 4.16 (2 H, qd, .1 = 7.12, 2.88 Hz), 3.96 (1 H, t, .1 EtO = 7.55 Hz), 3.18-3.16 (2 H, m), 2.44 (2 E: H, td, .1 = 11.85, 3.23 Hz), 0 (3 H, m), 1.74-1.73 (1 H, m), 151-149 (2 H, m), 1.37-1.36 (2 H, m), 1.22 (3 H, t, .1: 7.13 Hz). 0 o ): 7.35-7.17 (9 H, m), 4.20-4.13 (3 H, m), 3.28 (2 H, m), 2.48-2.47 (2 H, 1 1C m), 195-192 (3 H, m), 1.77-1.75 (1 H, m), 1.55-1.35 (3 H, m), 1.23-1.15 (1 H, (:1 Q m), 1.22 (3 H, t, .1: 7.14 Hz).
Intermediate Structure lH NMR/5 0 O (CDC13): 7.37-7.26 (3 H, 111), 7 (5 H, m), .16 (3 H, m), 3.32 (2 H, 11d d, J = 7.39 Hz), 2.58-2.41 (2 H, m), 1.97-1.95 (3 H, m), 1.81-1.80 (1 H, m), 1.44 (3 H, m), 1.30-1.18 (1 H, m), Cl 1.24 (3 H, t, J = 7.14 Hz).
(CDC13): 7.29 (4 H, m), 7.21-7.09 (4 H, EtO m), 4.19-4.09 (3 H, m), 3.59-3.45 (2 H, lle C| m), 2.53—2.43 (2 H, m), 1.97—1.94 (4 H, m),1.61—1.60(2 H, m), 1.48-1.45 (1 H, Cl m), 1.39-1.38 (1 H, m), 1.21 (3 H, t, J = 7.15 Hz).
EtO (CDCl3): 7.37 (1 H, d, J = 2.04 Hz), 11f 7.31-7.25 (2 H, m), 7.20-7.14 (5 H, m), 4.15-4.14 (3 H, m), 3.24 (2 H, d, J = Cl C! 7.44 Hz), (CDClg): 7.31-7.14 (8 H, m), 4.16-4.15 EtO (3 H, m), 3.24 (2 H, d, J = 7.43 Hz), 11g CI 260-243 (2 H, m), 2.02-1.90 (3 H m), 1.87-1.80 (1 H, 111), 9 (3 H, m), CI 134-124 (1 H, m), 1.24 (3 H, t, J = 7.13 Hz).
(CDC13): 8.05 (1 H, dd, J = 7.91, 1.50 Hz), 7.53 (1 H, td, J = 7.52, 1.53 Hz), 7.44 (1 H, td, 1 = 7.68, 1.47 Hz), 7.35 (1 H, d, J = 7.65 Hz), 7.29 (2 H, m), 7.16- 7.15 (3 H, m), 4.39 (1 H, t, J = 7.20 Hz), 4.21-4.09 (2 H, m), 3.56—3.42 (2 H, m), 3.11 (3 H, s), 2.59-2.49 (1 H, m), 2.48— 2.39 (1 H, m), 1.98-1.86 (3 H, m), 1.84- 1.76 (1 H, m), 1.60-1.33 (3 H, m), 1.22-1.15 (1 H, m), 1.21 (3 H, t, J = 7.13 Hz).
(CDC13): 7.45 (1 H, s), 7.32-7.24 (2 H, EtO m), 7.21-7.15 (3 H, m), 6.96 (2 H, m), 11) 4.47 (1 H, s), 4.17-4.16 (2 H, m), 3.33 /N (2 H, m), 2.69 (1 H, m), 2.49 (3 H, s), 1.97 (4 H, m), .48 (2 H, m), 1.30 (1 H, m), 1.24 (3 H, t, 1 = 7.13 Hz).
(CDCl3): 8.65 (1 H, s), 8.64 (1 H, s), 7.33-7.28 (2 H, m), 7.22-7.17 (3 H, m), 7.13 (1 H, t,J=4.95 Hz), 4.55 (1 H, m), 4.25-4.18 (2 H, m), 3.70-3.50 (2 H, m), 2.80 (1 H, m), 2.53 (1 H, m),2.17 (1 H, m), 2.09-1.97 (3 H, m),1.69-1.42 (4 H, m), 1.27 (3 H, t, J = 7.12 Hz).
Intermediate Structure lH NMR/S (CDC13): 7.76 (1 H, td, J = 7.80, 0.78 Hz), 7.51 (1 H, d, J =7.71 Hz), 7.41 (1 H, d, J = 7.88 Hz), .26 (2 H, m), 7.22-7.17 (3 H, m), 4.61 (1 H, dd, J = 8.73, 5.96 Hz), 4.21 (2 H, qd, J = 7.14, 1.24 Hz), 3.56-3.35 (2 H, m), 2.78-2.77 (1 H, m), 2.48—2.47 (1 H, m), 2.01 (4 H, m), 1.51-1.50 (3 H, m), 1.35-1.26 (1 H, m), 1.28 (3 H, t, J = 7.14 Hz).
(CDC13): 8.34 (1 H, dd, J = 4.65, 1.63 Hz), 7.64 (1 H, dd, J = 8.01, 1.56 Hz), 7.31 (2 H, m), 7.25-7.18 (3 H, m), 7.10 (1 H, dd, J = 7.98, 4.74 Hz), 4.58 (1 H, dd, J = 8.13, 6.40 Hz), 4.22 (2 H, q, J = 7.13 Hz), 3.62—3.39 (2 H, m), 2.81 (1 H, m), 2.53 (1 H, m), 2.20-1.95 (4 H, m), 1.68-1.41(4 H, m), 1.28 (3 H, t, J = 7.12 Hz).
(CDC13): 8.40 (1 H, d, J = 5.17 Hz), 7.31 (2 H, m), 7.19 (3 H, m), 7.02 (1 H, EtO s), 6.96 (1 H, d, J = 5.17 Hz), 4.18 (2 11n / H, m), 3.96 (1 H, t,J=7.46 Hz), 3.14 (2 H, m), 2.54 (3 H, s), 260245 (2H, m), 1.97 (2 H, m), 1.86-1.80 (1 H, m), 1.64—1.40 (2 H, m), 1.34-1.28 (1H, m), 1.25 (3 H, t, J =7.18 Hz).
(CDC13): 7.67 (1 H, d, J = 3.33 Hz), 7.30-7.29 (2 H, m), 7.22-7.18 (4 H, m), 4.45 (1 H, m), 4.22 (2 H, qd, J = 7.13, 3.54 Hz), 3.65-3.50 (2 H, m), 2.71 (1 H, m), 2.51250 (1 H, m), .95 (4 H, m), 1.50-1.31 (4 H, m), 1.27 (3 H, t, J = 7.12 Hz).
(CDCl3): 8.51 (1 H, d, J = 4.76 Hz), 7.59 (1 H, t, J = 7.45 Hz), 7.32-7.30 (2 EtO H, m), 7.25-7.08 (5 H, m), 4.51 (1 H, t, 11p J = 7.50 Hz), 4.18 (2 H, m), 3.45-3.28 /N (2 H, m), 2.69 (1 H, m), 2.48 (1 H, m), 2.07-1.87 (4 H, m), 1.64-1.28 (4 H, m), 1.23 (3 H, t, J = 7.15 Hz).
(CDCl3): 8.34 (1 H, d, J -—- 5.09 Hz), 7.32-7.26 (2 H, m), 7.22-7.14 (3 H, m), EtO 7.02 (1 H, s), 6.93 (1 H, d, J = 5.25 Hz), llq 4.49 (1 H, t, J = 7.40 Hz), 4.17 (2 H, qd, J = 7.13, 1.64 Hz), .27 (2 H, m), 2.71-2.64 (1 H, m), 252-241 (1 H, m), 2.31 (3 H, s), 207-188 (4 H, m), 1.62- 1.30 (4 H, m), 1.23 (3 H, t, J = 7.13 Hz).
(CDC13): 8.66 (1 H, d, J = 5.07 Hz), J 7.43 (1 H, s), 736-726 (3 H, m), 7.20- 7.14(3 H, m), 4.51 (1 H, m), 4.19(2 H, qd, J = 7.12, 2.51 Hz), .43 (2 H, m), 273-272 (1 H, m), 2.50-2.48 (1 H, m), 2.01 (4 H,m), 1.66-1.32 (4 H, m), 1.25 (2 H, t, J = 7.13 Hz).
Intermediate ure 'HNMR/s O O (CDC13): 7.47 (2 H, m), 7.41 (2 H, m), EtO 7.29 (2 H, m), 7.19 (3 H, m), 4.18 (2 H, lls F C m), 3.98 (1 H, t, J = 7.53 Hz), 3.25 (2 H, m), 2.56-2.41 (2 H, m), 1.96 (3 H, m), 1.79(1 H, m), 1.61-1.36 (3 H, m), 1.32- 1.25 (1 H, m), 1.23 (4 H, t, J = 7.16 Hz).
(CDC13): 7.35-7.28 (2 H, m), 720—719 (3 H, m), 6.73 (1 H, d,J= 1.15 Hz), 4.39 (1 H, m), 4.20 (2 H, m), 3603.43 (2 H, m), 2.78-2.66 (1 H, m), 2.56-2.45 (1 H, m), 2.39 (3 H, d, J = 1.01 Hz), 2.06-1.95 (4 H, m), 153-134 (4 H, m), 1.27 (3 H, t, J = 7.14 Hz).
(CDCl3): 7.31-7.26 (2 H, m), 7237.09 (5 H, m), 6.88-6.81 (2 H, m), 4.18-4.09 11u (3 H, m), 3.85 (3 H, s), 3.15 (2 H, d, J = 7.39 Hz), 2.52-2.40 (2 H, m), 2.01187 (3 H,m), 1.84-1.73 (1 H, m), 1.57-1.28 (4 H, m), 1.20 (3 H, t, J = 7.13 Hz). ): .29 (3 H, m), 7.21-7.15 (3 H, m), 6.42 (1 H, d, J = 7.19 Hz), 6.31 (1 H, d, J = 8.43 Hz),4.48 (1 H,t,J 11v = 7.21 Hz), 4.23—4.10 (2 H, m), 3.29— 3.12 (2 H, m), 3.04 (6 H, s), 2.65 (1 H, m), 2.47 (1 H, m), 2.05-1.91 (4 H, m), 1.54-1.35 (4 H, s), 1.23 (2 H, t, J = 7.13 Hz).
(CDC13): 0 (8 H, m), 4.17-4.16 (2 H, m), 3.89 (1 H, m), 3.13 (2 H, m), 11w 2.49 (2 H, m), 2.01-1.85 (3 H, m), 1.78 (1 H, m), 1.67-1.29 (4 H, m), 1.23 (3 H, t, J = 6.99 Hz). ): 7.31—7.26 (2 H, m), 7.23-7.15 (4 H, m), 7.12—7.08 (1 H, dd, J = 8.41, EtO 2.65 Hz), 6.89 (1 H, td, 1 = 8.30, 2.65 11x Hz), 422-409 (3 H, m), 3.24 (2 H, d, J = 7.47 Hz), 2.57-2.40 (2 H, m), 2.00- Cl 1.89 (3 H, m), 1.82-1.74 (1 H, m), 1.60- 1.54(1 H, m), 1.51-1.37 (2 H, m), 1.26- 1.18(1 H, m), 1.23 (3 H, t,J=7.13 Hz).
(CDClg): 7.31-7.26 (2 H, m), 7.20-7.15 (4 H, m), 6.80-6.77 (2 H, m), 4.22-4.08 (2 H, m), 4.02 (1 H, 1,1 = 7.56 Hz), 3.16 (2 H, d, 1 = 7.61 Hz), 2.60-2.41 (2 H, m), 1.97-1.91 (3 H, m), 1.86-1.77 (1 H, m), 1.61-1.39 (2 H, m), 1.23 (3 H, t, J = 7.14 Hz).
WO 29074 Intermediates 11 were converted to Intermediates 12 in Table 4 below, as described for the preparation of 12a in Example 6.
Table 4: Substituted 2-thioxo—2 3—dih dro- rimidineones.
Compound Structure LCMS 0 Cl HN (Method A) 12b SAN 1 R: 4.10 min H (M+H)+ = 411 0 CI HN (Method A) 12c SAN | Rt = 4.27 min H (M+H)+ = 445 4., : 0 Cl (Method C) 12d A l R,=4.16 min H (M+H)+ = 445 0 CI d A) R‘ = 4.35 min 126 HN SAN l (Mm)+ = 445 w : o c: HN No LCMS or NMR data 12f SAN | available (MX82705-154— H 04).
., : Compound Structure LCMS (Method C) R[ = 348 min (M+H)+ = 455 (Method A) 121 A | Rt = 2.46 min 3 n (M+H)+ = 392 N / N “N (Method A) 12-J 5 R, = 3.10 min (M+H)+ = 379 d C) RI = 3.91 min 446 (M+H)+ O CI (Method A) Rt = 3.68 min (M+I-1)Jr = 412/414 (Method C) 12m Rt = 2.28 min (M+H)+ = 392 821_1):KZA WO 29074 Compound 1 Structure LCMS S / N HN (Method A) 125 [ Rt=3.51 min N (M+H)+ = 398 0 <3 HN (Method A) 12‘ SAN I R‘ = 3.98 min H (M+H)+ = 407 (Method C) R = 2.43 min (M+H)+ = 421 (Method C) m ”/1: 1 Rt=3.90 min 3 u (M+H)+ = 413 0 Cl (Method A) 12w H/J/r: I R‘=4.19 min 8 ” (M+H)+ = 429/431 Compound ure LCMS O F (Method C) 12X '3: | R‘ = 3.96 min 3 u (M+H)+ = 413 O F HN (Method A) 12y SAN l R, = 4.01 min H (M+H)+ = 413 (Method A) 122 '1‘: I R,=4.14 min 3 n (M+H)+ = 429 Intermediates 12 were converted to Compounds 3 in Table 5 below, as for the preparation of nd 3b in e 6.
Table 5: 5-Substituted E 4—c clohex 1 -1H- rimidine-Z 4-di0nes.
Example Compound Structure 1H NMR/ 6 LCMS (DMSO—dé): 11.07 (1 H, s), 10.47 (1 H, O s), 722-720 (10 H, HN m), 3.72 (2 H, s), A 1 2.87-2.85 (1 H, m), (Method B) 0 N 2'54'2'44 (1 H? m)? 8 3a R1 = 4.94 min © 1.91-1.72 (4 H, m), (M+H)'*= 361 1.49—1.38 (4 H, m).
(E)—5—Benzy1-6—(4- phenylcyclohexyl)'ll~l~ pyrimidine-2,4-dione Example Compound I Structure 1H NMR / 5 LCMS (DMSO—dé): 11.14 (1 H, 5), 10.58 (1 H, s), 7.44 (1 H, dd, J = 0 Cl 7.47, 1.80 Hz), 7.22- 7.21 (7 H, m), 7.08 CAN 1 (1 H, dd, J = 7.28, (Method B) 2.13 Hz), 3.78 (2 H, H Rt = 5.25 min -, : s), 2.70-2.57 (1 H, (M+H)+ = 395 m), 2.48-2.43 (1 H, m), 1.95-1.80 (2 H, (E)—5-(2-Chlorobenzyl)—6- m), .72 (2 H, (4-pheny1cyc10hexy1)—1H— m), 1.48 (2 H, d, J = pyrimidine-2,4—dione 12.39 Hz), 1.39-1.35 (2 H, m).
(DMSO—a’é): 11.15 —_‘1 (1 H, s), 10.60 (1 H, s), 7.49 (1 H, dd, J = 7.98, 1.47 Hz), 7.26- 0 CI 7.25 (3 H, m), 7.19- HN 7.17 (3 H, m), 7.05 CAN 1 (1 H, dd, J = 7.81, (Method B) 3d H 1.45 Hz), 3.82 (2 H, Rt = 5.53 min s), 2.65—2.62 (1 H, (M+H)+ = 429 m), 2.48-2.44 (1 H, m), 1.91—1.88 (2 H, (E)—5—(2,3-Dichlorobenzy1)- m), 1.78-1.75 (2 H, 6-(4-phenylcyc10hexy1)-1H~ m), 1.57-1.46 (2 H, pyrimidine-2,4-dione m), 1.41-1.38 (2 H, m). _j_ (DMSO—a’s): 11.06 CI (1 H, s), 10.42 (1 H, 0 CI s), 7.48 (2 H, d, J = 8.04 Hz), 7.28-7.27 CAN [ (3 H, m), 7.15-7.14 (Method B) 11 3e (3 H, m), 4.03 (2 H, R‘ = 5.31 min s), 2.47-2.39 (1 H, (M+H)+ = 429 m),1.75—1.71 (5 H, m), 1.15-1.11 (4 H, (2,6-Dich10robenzy1)- m). 6—(4-phenylcyclohexyl)-1H— pyrimidine-2,4-dione (DMSO-dé): 11.16 (1 H, s), 10.6] (1 H, s), 7.61 (1 H, d, J = 2.21 Hz), 7.36-7.23 0 C1 (3 H, m), 7.20-7.14 CAN 1 (3 H, m), 7.10 (1 H, (Method B) d, J = 8.42 Hz), 3.74 12 3f R, = 5.68 min H (2 H, s), 2.70-2.58 " © (M+H)+ = 429 (1 H, m), 2.48-2.43 (1 H, 1-1.88 (2 H, m), 1.81—1.77 (2,4—Dichlorobenzy1)- (2 H, m), 1.56-1.41 6—(4—phenylcyclohexyl)—1 H- (2 H, m), 1.45—1.34 pyrimidine—2,4-di0ne (2 H, m).
Example Compound Structure 1H NMR / 6 LCMS (DMSO—dé): 1 1.15 (1 H, s), 10.61 (1 H, 0 Cl s), 7.50 (1 H, d, J = 8.53 Hz), 7.29-7.28 (3 H, m), 7.16-7.15 (Method B) (4 H, m), 3.78 (2 H, 13 3g R = 5.45 min s), 2.74-2.62 (1 H, (M+H)+ = 429 m), 249—242 (1 H, m), 1.92—1.88 (2 H, (E)—5—(2,5—Dichlorobenzyl)- m), 1.81-1.77 (2 H, henylcyclohexyl)— 1 H- m), 1.46-1.42 (4 H, pyrimidine-2,4—dione W_#* dfi): 1 1.17 (1 H, s), 10.63 (1 H, s), 7.95 (1 H, dd, J = 7.92, 1.42 Hz), 7.61 (1 H, td, J = 7.58, 1.45 Hz), 7.47—7.45 (1 H, m), 726—724 (Method B) (2 H, m), .16 14 31 R, = 4.41 min (4 H, m), 4.14 (2 H, (M+H)+ = 439 s), 3.37 (3 H, s), 2.83-2.79 (1 H, m), (E)-5—(2— 2.47244 (1 H, m), Methanesulfonylbenzyl) 1.89—1.86 (2 H, m), (4—phenylcyclohexyl)— 1 H- 1.80-1.70 (2 H, m), pyrimidine-2,4—dione 6 (2 H, m), 1.47-1.34 (2 H, m). +_ (DMSO-dé): 11.04 (1 H, 3), 10.48 (1 H, s), 7.54 (1 H, t, J = 7.66 Hz), .24 (2 H, m), 7.23—7.15 (3 H, m), 7.03 (1 H, d, J = 7.60 Hz), 6.98 (Method B) (1 H, d, J = 7.72 Rt = 3.04 min Hz), 3.79 (2 H, s), (M+H)+ = 376 3.11—3.03 (1 H, m), (E)-5~(6-Methylpyridin 2.58-2.52 (1 H, m), ylmethyl)~6-(4- 2.41 (3 H, s), 1.84— phenylcyclohexyl)— 1 H- 1.83 (4 H, m), 1.60- pyrimidine—2,4—dione 1.48 (2 H, m), 1.53— (isolated as hydrochloride) 1.41 (2 H, m).
(DMSO—dé): 11.03 (1 H, s), 10.49 (1 H, s), 8.70 (2 H, d, J = 4.89 Hz), 7.28-7.27 (3 H, m), 7.19—7.17 (Method B) (3 H, m), 4.02 (2 H, 16 3k R, = 3.73 min s), 2.80—2.77 (1 H, (M+H)+ = 363 m), 2.49-2.44 (1 H, m), 1.85-1.82 (4 H, (E)(4-Phenylcyclohexyl)— m), 1.50 (2 H, d, J = —pyrimidinylmethyl-1H- 12.32 Hz), 1.47-1.31 pyrimidine-2,4-dione (2 H, m).
Example Compound Structure ‘H NMR/s LCMS (DMSO—ds ): 11.11 (1 H, 3), 10.55 (1 H, s), 7.98 (1 H, t, J = 7.83 Hz), 7.70 (1 H, d, J = 7.69 Hz), 7.55 (1 H, d, J = 7.93 Hz), 7.28 (2 H, t, J = 17 31 7.48 Hz), 7.18-7.17 (4 H, m), 3.94 (2 H, s), 3.03 (1 H, s), (E)—5—(6- 1.86—1.81 (4 H, m), Trifluoromethylpyridin 1.50(4 H, dd, .1 = y1methy1)—6-(4- 33.29, 12.83 Hz). phenylcyclohexy1)-1H— dine-2,4—dione (DMSO—dé): 1 1.02 (1 H, 5), 10.50 (1 H, !\ s), 8.40 (1 H, dd, J = ON/Cl 4.66, 1.46 Hz), 7.89 (1 H, dd, J = 8.03, 0%” 1.47 Hz), 7.27-7.25 (3 H, m), 7.18-7.15 (Method B) 18 3m o (3 H, m), 3.98 (2 H, R, = 4.57 min s), 2.69—2.66 (1 H, (M+H)+ = 396 m), 2.48-2.43 (1 H, (E)—5-(3—Ch10ropyridin—2- m), 1.87-1.84 (2 H, y1methy1)—6-(4- m), 1.81-1.70 (2 H, phenylcyclohexy1)-1H— m), .49 (2 H, pyrimidine—2,4-dione m), 1.45—1.30 (2 H, \ (DMSO-d6): 1 1.11 l (1 H, s), 10.53 (1 H, O s), 8.28 (1 H, d, J = .14 Hz), 7.23-7.20 CAN 1 (5 H, m), 7.07 (1 H, s), 6.99 (1 H, d, J = (Method B) 19 3n ., : 5.24 Hz), 3.69 (2 H, R, = 2.96 min s), 2.82-2.74 (1 H, (M+H)+ = 376 m), 255-250 (1 H, (E)—5-(2—Methy1pyridin—4- m), 2.40 (3 H, s), y1methy1)—6—(4- 195—175 (4 H, m), phenylcyclohexy1)-1H— 149—145 (4 H, m). pyrimidine-2,4-dione (DMSO-d6): 11.16 S/N (1 H, s), 10.6] (1 H, s), 7.67 (1 H, d, .1 = 3.32 Hz), 7.52 (1 H, d, .1 = 3.32 Hz), ' (Method B) .14 (5 H, m), 3o Rt = 4.09 min 4.07 (2 H, s), 3.01— (M+H)Jr = 368 2.89 (1 H, m), 2.58- 2.52 (1 H, m), 1.87- (E)—6-(4-Phenylcyclohexy1)— 1.84 (4 H, m), 1.62- —thiazol—2—y1methy1-1 H— 1.58 (2 H, m), 1.50— pyrimidine-2,4-dione 1.48 (2 H, m). 821_1):KZA I Example Compound Structure 1H NMR / 5 LCMS /—( (DMSO— d6): 11.15 —‘ (1 H, 5), 10.61 (1 H, S /N O s), 727—715 (5 H, m), 7.03 (1 H, d, J = l 1.12 Hz), 4.00 (2 H, o N 81295 (1 H, m), (Method B) 3t H 2.52 (1 H, m), 2.28 R, = 4.26 min ”Q (3 H, d, 1 = 1.04 Hz) (M+H)+ = 382 1.87-1.83 (4 H, m), (4-Methylthiazol 1154-1 .51 (4 H, m). y1)—6—(4- Phenylcyclohexy1)—1H— dine-2,4-dione (DMSO- d6): 11.07 (1 H, s), 10.49 (1 H, 0 O s), 7.27 (2 H, m), 7.17—7.16(4 H, m), A l 6.97 (2 H, :11), 6.84 (Method B) 26 3u E (1 H’ td’ J,‘ 7'42’ R, = 4.95 min © 1.08 Hz), 3.86 (3 H, (M+H)+ 8), 3.64 (2 H, s), 2.74-2.71 (1 H, m), (E)-5~(2—Meth0xybenzyl)—6— 1.83 (4 H,m), 1.40— (4-phenylcyclohexy1)—1H- 1.37 (4 H, m). pyrimidine-2,4~dione L_ (DMSO- d6): 1 1.00 (1 H, s), 10.40 (1 H, s), 7.36 (1 H, dd, 1 = 8.42, 7.29 Hz), 7.27 (2 H, m), 7.17 (3 H, m), 6.45-6.33 (2 H, m), . (Method B) 27 3v 3.65 (2 H, s), 2.99 (6 Rt = 3.22 min H, s), 1.85-1.81 (4 (M+H)+ = 405 H, m), 1.47 (4 H, (E)(6- m).
Dimethylaminopyridin—2- y1)methy1—6-(4- phenylcyclohexyl)—1H— pyrimidine-2,4-dione F (DMSO- d6): 11.13 F (1 H, 5), 10.53 (1 H, s), 7.27-7.24 (7 H, O m), 7.07 (1 H, 5), 3.73 (2 H, s), 2.85 (1 A I H, m), 1.94-1.75 (4 (Method B) 28 3w 0 H H, m), 1.50—1.47 (4 R, = 5.02 min '1ql© H, m). (M+H)+ = 397 (E)(3,4—Diflu0r0benzy1)~ 6-(4-phenylcyclohexy1)-1H- pyrimidine-2,4-dione Example Compound Structure lH NMR/S LCMS F (DMSO— d6): 11.16 (1 H, 3), 10.61 (1 H, s), 7.45 (1 H, dt, J = 0 CI 8.70, 1.44 Hz), 7.28 (2 H, m), .15 A | (5 H, m), 3.75 (2 H, (Method B) O N s),2.65(1H,t,J— . _ , 29 3X H Rt — 5.33 mm © 12.12 Hz), 1.87-1.84 (M+H)+ : 413 (4 H, m), 1.57—1.34 (4 H, m).
(E)—5—(2-Chloro-4— fluorobenzy1)—6—(4— cyclohexy1)—1H- dine-2,4~dione F (DMSO- d6): 11.11 (1 H, 3), 10.53 (1 H, s), 7.27 (2 H, m), 0 F 7.18(5 H, m),6.98 (1 H, td, J = 8.43, A | 2.67 Hz), 3.69 (2 H, (Method B) 3y 0 u s), 2.78 (1 H, t, J = R, = 5.09 min O 12.03 HZ), 1.88—1.85 (M+H)+ = 397 (4 H, m), 1.47-1.44 (4 H, m).
(E)(2,4-Difluorobenzy1)— 6-(4-pheny1cyclohexy1)—1H- pyrimidine—2,4-dione F (DMSO— d6): 11.12 (1 H, 3), 10.56 (1 H, O F s),7.2l-7.l9(7 H, m), 6.97 (1 H, t, J = A I 7.16 Hz), 3.77 (2 H, (Method B) O N s), 2.77 (1 H, m), 31 32 .
H Rt — 5.05 mm_ Q 1.86-1.83 (4 H, m), (M+H)+ = 397 1.47 (4 H, m).
(E)(2,3—Diflu0r0benzy1)~ 6—(4-pheny1cyc10hexy1)-l H- pyrimidine—2,4—dione F (DMSO— d6): 11.11 Cl (1 H, 3), 10.53 (1 H, s), 7.45 (1 H, dd, J = O 7.28, 2.14 Hz), 7.25— 7.24 (7 H, m), 3.72 A | (2 H, s); 2.89 (1 H, (Method B) O N m), 1.93—1.75 (4 H, . 32 3aa H Rt — 5.22 mm_ O m), 1.51-1.48 (4 H, (M+H)+ = 413 (E)—5-(3-Ch10r0—4- fluorobenzy1)(4— phenylcyclohexy1)- 1 H- pyrimidine-2,4-dione | Example Compound Structure 1H NMR / 6 LCMS (DMSO- d6): 11.01 (1 H, 3), 10.49 (1 H, s), 7.37—7.33 (2 H, m), 7.32—7.24 (4 H, m), .13 (4 H, (Method B) 33 3bb m), 3.71 (2 H, s), R: 11.01 min 2.99 (1 H, br s) (M+H)+ = 361 2.85-2.74 (1 H, m), 2.17-2.03 (2 H, m), 1.82-1.66 (4 H, m), .14 (2 H, m).
(DMSO- d6): 11.02 NH2 (1 H, 3), 10.45 (1 H, s), 7.31—7.20 (5 H, O m), 7.19—7.13 (1 H, m), 6.27-6.19 (2 H, (Method D) 34 3cc ¢J\ m), 5.76 (2 H, s), Rt = 3.00 min 0 N 3.61 (2 H, s), 2.98— (M+H)+ = 377 H 2.85 (1 H, m) 2.56- Q 2.45 (1 H, m), 1.92— 1.72 (4 H, m), 1.57- 1.37 (4 H, m). 4- hen lc clohex l-lH— rimidine- 2,4—di0ne (13a! (E)—3—Methyl—5—(3—methylbenzyl)—6—(4—phenylcyclohexyl)—1H—pyrimidine-2,4-dione (13a). Sodium hydride (2.1mg; 0.053mmol) was added to a solution of nd 3h (20mg; 0.053mmol) in dry DMF (2mL), followed by the addition of3.3uL (0.053mmol) Mel The mixture was stirred at ambient temperature for 16h. A further leq. of NaH and Mel was added over the next 24h. The contents were diluted with water (0.5mL) and concentrated in vacuuo, and the resulting residue was purified by preparative LC (C18 column eluting with 30—95% CH3CN/H2O + 0.1% formic acid), to give the titled product (13mg) after freeze drying. 1H NMR 6 (ppm) (DMSO- d6): 10.76 (1 H, s), 7.28 (2 H, m), 7.18—7.17 (4H, m), .92 (3 H, m), 3.74 (2 H, s), 3.16 (3 H, s), 2.90 (1 H, s), 2.25 (3 H, s), 1.90—1.78 (4 H, m), 1.48 (4 H, m). LCMS d B): R: 5.56 minutes, (M+H)+ = 389.
Exam les 36—42: Pre aration of 5-Substituted E Alk 1—6- 4-c clohex l—1H— pyrimidine-2,4—diones e compounds in Table 6 below were prepared from appropriate compounds 3 with the requisite alkylating agents, such as described below for Examples 38-41. For related reactions describing alkylation of amines, see pages 397—408 of Larock, R.C.
Comprehensive Organic Transformations. New York: VCH Publishers, Inc., 1989, the contents of which are herein incorporated by reference in their entirety.
Table 6: 5-Substituted E rimidine-Z 4-diones.
Compound Structure NMR / 5 LCMS (DMSO- d6): 10.71 (1 H, s), 7.30—7.26 l O (2 .12-7.10 /N\/\N (4 H, m), 6.99—6.97 I (3 H, m), 3.90 (2 H, O u t, .1 ~ 6.88 Hz), 3.73 (Method B) 36 13b © (2H,s),2.89(1 H, (M+H)+=446 m), 2.41 (2 H, t, J = 6.88 Hz), 2.25 (3 (E)(2-Dimethylamino—ethyl)-5— H, s), 2.18 (6 H, s), (3—methyl—benzyl)(4—phenyl- 1.90—1.79 (4 H, m), cyclohexyl)-1H—pyrimidine—2,4- 1_46 (4 H, m). dione 1 (DMSO— d6): 11.00 ex (1H, s), 9.96 (1H, s), 7.49 (1H, dd), 0 CI 7.27 (3H, m), 7.17 (\NMN (3H, m), 7.08(1H, OJ 1 d), 3.96 (2H, d), 0 11 3.89 (2H, s) 3.85 (Method B) 37 13c Q (2H, t) 3.67 (2H, t) (Mm). = 556 3.40 (2H, d) 3.08 (4H, m) 2.71 (2H, t), 1.95 (4H, m), (E)(2,3-Dichloro-benzyl)(3- 1.79 (2H, d), 1.54 morpholin-4~yl~propyl)—6—(4- (2H, d), 1.43 (2H, phenyl-cyclohexyl)—1H—pyrimidine— m). 2,4-dione F (DMSO- d6): 10.82 F (l H, s), 7.63 (1 H, 5), (3H, m), 1 7.31-7.25 (2 H, m), 7.23714 (3 H, m), , (Method D) 38 13d 0 N 3.89 (2 H, s), 3.17 (M+H)t = 443 © (3 11,5). 3.01—2.87 (1 H, m), 2.57-2.38 (1 H, m), (E)-3 l—6—(4—phenyl- 4 (4 H, m), cyclohexyl)—5—(3-trifluoromethyl— 1.58-1.38 (4 H, m) benzyl)—1H-pyrimidine—2,4-dione 1 Example nd Structure NMR / 6 LCMS (CDC13): 9.08 (1 H, S), 7.51-7.36 (4 H, m), .27 (2H, m), 7.25-7.15 (3 H, m), 4.18 (2 H, t,J=6 HZ), (Method A): 39 13c 3.92-3.84 (4 H, m), (M+H)+ = 587 2.93—2.77 (1 H, m), 2.66—2.51 (1 H, m), -97 (2 H: m), (E)—3-[2-(tert-Buty1-dimethy1- 1‘79”] ~28 (4 H, m), silanyloxy)-ethy1]-6—(4-phenyl— 1'60']‘ 6 (2 Ha m), exyl)—5-(3-trifluoromethy1- 0.81 (9H b 1 -1H— . . d . -2 4-d . ’ S) , enzy ) pyr1m1 me mm _0_03 (6 H, s) (DMSO—dg): 10.77 (1 H15), 7.63 (1 H, s), 7.54— 7.49 (3 H, m), 7.31- 7.25 (2 H, m), 7.22— 7.14 (3 H, m), (Method D): 4.75 (1 H, t, 1 = 5.9 40 13f (M+H)+= HZ), 3.94-3.85 (4 H, m), 355-347 (2 H, m), (E)—3—(2-Hydroxy—ethyl)—6-(4- 298.287 (1 H, m), phenyl-cyclohexyl)—5—(3- 2552.44 (1 H, m), trifluoromethyl—benzy1)-1H— 1.97-1.73 (4 H, m), pyrimidine-2,4—dione 157—137 (4 H, m) (DMSO—d6): 10.81 (1 H, S), 7.62 (1 H, s), 755—747 (3 H, m), 731-725 (2 H, m), 723-714 (3 H, m), 4.00 (2 H, t), (Method D): 41 13g 3.88 (2 H, s), (M+H)+ = 487 3.50 (2 H, t, J = 6.7 HZ)! 3-24 (3 Ha S), (E)(2—Meth0xy-ethyl)-6—(4- 2H99-288 (1 H, m), phenyl-cyclohexy1)(3— -45 (1H: m), trifluoromethyl—benzy1)-1H- 1'97'1~73 (4 H: m), pyrimidine-2,4-dione 1.57—1.38 (4 H, m) (DMSO—dg): 10.77 (1 H, s), 7.33-7.10 (10 H, N m), 3.78 (2 H, s), 1 (Method D): 42 13h A 3.17 (3 H, s), (M+H)+ = 375 2.95-2.84 (1 H, m), ,“E: 2.56—2.44 (1 H, m), 1.96-1.74 (4 H, m), 154—140 (4 H, m) Exam le 38. Pre aration of E Meth l-6— 4- hen l-c clohex l-5— 3-triflu0r0meth 1- ben l-lH- rimidine-2 4-di0ne 13d Sodium hydride (6mg; 0.14mmol) was added to a solution of (E)- 6-(4-phenyl— cyclohexyl)-5—(3-trifluoromethyl—benzyl)—1H-pyrimidine-2,4—dione (3 b) (50mg; 0.1 ) in dry DMF (3mL), ed by the addition of 9uL (0.14mmol) methyl iodide after 30minutes. The reaction mixture was stirred at ambient temperature for 18 hours. A further 0.2 lents ofNaH and Mel was added and stirring continued for 2 hours and 25 minutes.
Then the contents were diluted with water (10mL). The mixture was extracted with ethyl acetate (2 X 20mL) and the organic phases were dried (NaZSO4), filtered and ated. The residue was recrystallised out of boiling methanol to afford the product, 10.2mg. R1: 5.63 minutes.
Sodium hydride (18mg; 0.46mm01) was added to a solution of (E)— 6—(4—phenyl- cyclohexyl)—5—(3-trifluoromethyl—benzyl)- 1 H-pyrimidine—2,4-dione (3b) (150mg; ol) in dry DMF (5mL), followed by the addition of 9uL (0.14mmol) of (2-bromo—ethoxy)-tert- butyl—dimethyl—silane after 25minutes at 80°C. The reaction mixture was stirred at 80°C for 18h. A further 2.5 equivalents ofNaH and Mel were added over 24 hours. The reaction mixture was diluted with water (10mL) and extracted with ethyl e (4 X 10mL) then the organic phase was dried (NazSO4), filtered and evaporated. The material was d by column chromatography g with a mixture of ethyl acetate and cyclohexane (0:1 to 1:0 by volume) to afford the title compound, 57mg. Rt =5.09 minutes.
Tetrabutylammonium fluoride (1M in THF, 141 uL; 0.141mm01) was added to a stirring solution of (E)[2-(tert-butyl—dimethyl-silanyloxy)~ethyl](4-phenyl-cyclohexyl)- -(3—trifluoromethyl-benzyl)—1H-pyrimidine-2,4-dione (13f) (55mg; 0.094mmol) in THF (5mL). The reaction mixture was stirred for 1 hour then left to stand for 5 days. Water (10mL) was added and the mixture was extracted with diethyl ether (2 X 10mL). The organics were dried (Na2804), filtered and evaporated. The material was d by column chromatography eluting with a mixture of ethyl e and cyclohexane (0:1 to 1:0 by volume) to afford the title compound, 20mg. R = 5.28 minutes.
Exam le 41. Pre aration of E trifluorometh l—ben l—lH- rimidine-2 4—di0ne 13
[0147] Sodium e (13mg; 0.316mmol) was added to a solution of (E)- 6—(4-phenyl— cyclohexyl)—5—(3 —trifluoromethyl—benzyl)—1H-pyrimidine-2,4—dione (3b) (104mg; 0.243mmol) in dry DMF (4mL), followed by the addition of 30uL (0.316mmol) of 1-bromo- oxyethane after 30minutes. The reaction mixture was stirred at 80°C for 42 hours.
The reaction mixture was diluted with water (10mL) and extracted with ethyl acetate (3 X 10mL) then the organic phases were dried (Na2804), filtered and evaporated. The material was purified by column tography eluting with a e of ethyl acetate and cyclohexane (0:1 to 1:0 by volume) then further purified by preparative LC (C18 column eluting with 10-98% CH3CN/H20 + 0.1% formic acid, to give the product after freeze , 7mg . Rt = 5.70 minutes.
Example 43: Glucocorticoid Receptor Binding Assay The ing is a description of an assay for determining the inhibition of dexamethasone binding of the Human Recombinant Glucocorticoid Receptor: Binding protocol: Compounds were tested in a binding displacement assay using human recombinant glucocorticoid receptor with 3H-dexamethasone as the ligand. The source of the receptor was recombinant baculovirus-infected insect cells. This GR was a full- length steroid hormone receptor likely to be associated with heat-shock and other endogenous The assay was carried out in v-bottomed 96-well polypropylene plates in a final volume of 100111 containing 0.5nM GR solution, 2.5nM 3H—dexamethasone (Perkin Elmer NETl 19200) in presence of test compounds, test compound vehicle (for total binding) or excess dexamethasone (2011M, to determine non-specific g) in an riate volume of assay buffer.
For the IC50 determinations, test compounds were tested at 6 concentrations in duplicate. Test compounds were d from lOmM stock in 100% DMSO. The tested solutions were prepared at 2x final assay concentration in 2% ssay buffer.
All reagents and the assay plate were kept on ice during the on of reagents.
The reagents were added to wells of a omed polypropylene plate in the following order: 25111 of lOnM 3H-dexamethasone solution, 50111 of TB/NSB/compound solution and 25111 of 2nM GR on. After the additions, the incubation mixture was mixed and incubated for 2.5hrs at 4°C.
After 2.5hrs incubation, unbound counts were removed with dextran coated al (DCC) as follows: 15111 of DCC solution (10% DCC in assay buffer) was added to all wells and mixed (total volume 115111). The plate was centrifuged at 4000rpm for 10 minutes at 4°C. 75111 of the supernatants was carefully pipetted into an ate. 150111 of scintillation cocktail were added (Microscint-40, Perkin Elmer). The plate was vigorously shaken for approx. 10 minutes and d on Topcount.
For the IC50 determinations, the results were calculated as % inhibition [3H]- dexamethasone bound and fitted to sigmoidal curves (fixed to 100 and 0) to obtain 1C50 values (concentration of compound that displaces 50% of the bound counts). The IC50 values were converted to K (the inhibition constant) using the Cheng—Prusoff equation. Test results are presented in Table 7.
Reagents: Assay buffer: 10mM potassium ate buffer pH 7.6 containing SmM DTT, lOmM sodium molybdate, lOOuM EDTA and 0.1% BSA.
Example 44: GR Functional Assay using SW1353/MMTV-5 cells SW1353/MMTV-5 is an adherent human osarcoma cell line that contains endogenous glucocorticoid receptors. It was transfected with a plasmid (pMAMneo-Luc) encodingfirefly luciferase located behind a glucocorticoid—responsive element (GRE) derived from a viral promoter (long terminal repeat of mouse mammary tumor virus). A stable cell line /MMTV—5 was selected with cin, which was required to maintain this plasmid. This cell line was thus sensitive to glucocorticoids (dexamethasone) leading to expression of luciferase (ECsod'ex 10nM). This dexamethasone-induced response was gradually lost over time, and a new culture from an earlier passage was started (from a cryo- stored aliquot) every three months.
In order to test for a GR—antagonist, SW1353/MMTV-5 cells were incubated with several dilutions of the compounds in the presence of d'ex (SOnM), and the inhibition of d luciferase expression was ed using luminescence detected on a Topcount (Britelite Plus kit, Perking . For each assay, a dose—response curve for dexamethasone was prepared in order to determine the ECso required for calculating the K from the IC50's of each tested compound.
SW1353/MMTV—5 cells were distributed in 96-well plates and incubated in medium (without geneticin) for 24hrs. Dilutions of the compounds in medium + SOnM dexamethasone were added and the plates further ted for another 24hrs after which the luciferase expression is measured.
Table 7: Activity data for selected compounds.
GR GR Compound Structure Binding Functional K K 2a + + GR GR nd Structure Binding Functional Ki Ki 2b '3: | ++ ++ 0 N o 2c ++ + 2d + + 3a DAN | +++ +++ 3b HN ++ +++ CAN [ u : O C! 3"c 02m I +++ +++ GR 1 GR Compound ure Binding Functional J Ki Ki 0 Ci 3d 3: I +++ +++ O N 4,, : 0 Cl 3e *3: | ++ ++ O N 0 CI 3f HN ++ +++ DAN [ O C! 3g :1: l +++ +++ O N H, : 3ha ¢kfigl +++ +++ O N 3j :1: t + ++ O N WO 29074 PCT/U82012/029376 GR GR Compound Structure Binding Functional Ki Ki N /N 3k I + + 31 ++ +++ o Cl 3m CAN | + + 3n CAN l + — S / N i + + O N 3P CAM i + + 2012/029376 GR GR Compound Structure Binding Functional K K 3q + +++ 3r + ++ ++ ++ 3t | + + O N 0 Ce 3 u CAN I +++ ++ 3v ++ +++ PCT/U82012/029376 GR GR Compound ure Binding Functional K; K 3w HN + ++ CAN I [I © 0 CI 3x HN + +++ CAN l F 1 O F 3y HN ++ ++ CAN 1 32 Hi: I +++ +++ 3aa HN + +++ CAN ! PCT/U82012/029376 GR GR Compound ure Binding Functional K K 3bb + - 12g ‘1‘: i + + S N ., : 13a i 1 ++ +++ O N I O /N\/\ 13b l + + o N 0 c: 1 30 + + 1 3d ++ + PCT/U82012/029376 GR GR Compound Structure g Functional Ki Ki 13f + + 13g + + 3cc :1 I + + 13h 0%” l + ++ In Table 7, GR Binding compounds with a K value of less than 5.0 nM are designated with +++; compounds with a K value of 5.0 nM to 10.0 nM are designated with ++; and compounds with a K value greater than 10 nM are designated with +. GR Functional compounds with a K value of less than 50 nM are designated with +++, compounds with a Kg value of 50 nM to 100 nM are designated with ++; and compounds with a K value greater than 100 nM are designated with +. gh the foregoing ion has been described in some detail by way of illustration and example for purposes of clarity of understanding, one of skill in the art will appreciate that certain changes and modifications may be practiced within the scope of the appended claims. In addition, each reference provided herein is incorporated by reference in its entirety to the same extent as if each reference was individually incorporated by reference.
Where a conflict exists between the instant application and a nce provided herein, the instant application shall dominate.

Claims (19)

We Claim:
1. A compound of formula I: R2 L1 R1 X N wherein 5 the dashed line is absent or a bond; X is selected from the group consisting of O and S; R1 is selected from the group consisting of C3-12 cycloalkyl, C3-20 heterocycloalkyl, aryl and heteroaryl, optionally substituted with from 1 to 3 R1a ; 10 each R1a is independently selected from the group consisting of H, C1-6 alkyl, C2-6 l, C2-6 alkynyl, C1-6 alkoxy, C1-6 alkyl-OR1b, halogen, C1-6 haloalkyl, C1-6 haloaloxy, -OR1b, -NR1bR1c, -C(O)R1b, -C(O)OR1b, -OC(O)R1b, -C(O)NR1bR1c, -NR1bC(O)R1c, -SO2R1b, -SO2NR1bR1c, C3-12 cycloalkyl, C3-20 heterocycloalkyl, aryl and aryl; 15 R1b and R1c are each independently selected from the group consisting of H and C1-6 alkyl; R2 is selected from the group consisting of H, C1-6 alkyl, C1-6 alkyl-OR1b, C1-6 alkyl-NR1bR1c and C1-6 alkylene- C3-20 heterocycloalkyl; R3 is selected from the group consisting of H and C1-6 alkyl; 20 Ar is aryl, ally substituted with 1-4 R4 groups; each R4 is ndently selected from the group consisting of H, C1-6 alkyl, C1-6 alkoxy, halogen, C1-6 haloalkyl and C1-6 haloalkoxy; L1 is a bond or C1-6 alkylene; wherein each lkyl group is a saturated or partially unsaturated, 25 clic, fused bicyclic or bridged polycyclic ring assembly, wherein each heterocycloalkyl group contains 1 to 5 heteroatoms selected from N, O, and S, optionally oxidized, (10249821_1):KZA n each aryl group is a polyunsaturated, aromatic, hydrocarbon substituent which can be a single ring or multiple rings which are fused together or linked covalently, n each heteroaryl is an aryl group containing 1 to 4 heteroatoms selected 5 from N, O, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and wherein the nitrogen atom(s) are optionally quaternized, subscript n is an integer from 0 to 3, and salts and enantiomers, racemates, diastereomers, tautomers or ric isomers thereof. 10
2. The compound of claim 1, having formula Ia: R2 L1 R1 X N (Ia).
3. The compound of claim 1, having formula Ib: O R1 O N (Ib).
4. The compound of claim 1, having formula Ic: (R1 )1-4 O N 15 (Ic).
5. The compound of any one of claims 1 to 4, wherein R1 is selected from the group consisting of aryl and heteroaryl. (10249821_1):KZA
6. The compound of any one of claims 1 to 5, wherein R1 is selected from the group consisting of phenyl, l, pyrimidine, and thiazole.
7. The compound of any one of claims 1 to 6, wherein each R1a is independently selected from the group consisting of H, C1-6 alkyl, C1-6 alkoxy, halogen, 5 C1-6 haloalkyl, -NR1bR1c, and -SO2R1b.
8. The compound of any one of claims 1 to 7, wherein each R1a is C1-6 haloalkyl.
9. The compound of any one of claims 1 to 7, wherein each R1a is independently selected from the group consisting of H, Me, Et, -OMe, F, 10 Cl, -CF3, -NMe2, and -SO2Me.
10. The compound of any one of claims 1 to 7, wherein each R1a is -CF3.
11. The compound of any one of claims 1 to 10, wherein R2 is selected from the group consisting of H and C1-6 alkyl.
12. The nd of any one of claims 1 to 11, wherein R2 is H. 15
13. The compound of any one of claims 1 to 9, selected from the group ting of: O O O Cl HN HN HN O N O N O N H H H , , , O Cl O Cl O Cl HN HN HN O N O N O N H H H , , , (10249821_1):KZA O Cl O O S NH NH NH O N O N O N H H H , , , N N N O O O NH NH N O N O N O N H H H , , , N N O O Cl O NH NH NH O N O N O N H H H , , , S N N N O O O NH NH NH O N O N O N H H H , , , 821_1):KZA F F F F F F N S N O O O NH NH NH O N O N O N H H H , , , N F O O O O NH NH NH O N O N O N H H H , , , F F O Cl O F O F NH NH NH O N O N O N H H H , , , O O O NH N N O N O N O N H H H , , , O Cl O N N N O N O N H H 5 and . 821_1):KZA
14. The compound of any one of claims 1 to 13, having the formula: O N
15. A pharmaceutical composition comprising a pharmaceutically acceptable ent and a compound of any one of claims 1 to 14. 5
16. Use of a compound of any one of claims 1 to 14, in the manufacture of a medicament for treating a disorder or ion indicating administration of a glucocorticoid receptor modulator.
17. Use of the compound of any one of claims 1 to 14, in the manufacture of a medicament for treating a disorder or condition indicating administration of a 10 glucocorticoid receptor antagonist.
18. The use of claim 17, in the manufacture of a medicament wherein the disorder or ion is selected from the group consisting of obesity, es, cardiovascular disease, hypertension, Syndrome X, depression, anxiety, glaucoma, human deficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS), 15 neurodegeneration, Alzheimer's disease, Parkinson's disease, cognition enhancement, Cushing's Syndrome, Addison's Disease, osteoporosis, frailty, muscle frailty, inflammatory diseases, osteoarthritis, rheumatoid arthritis, asthma and rhinitis, adrenal function-related ailments, viral infection, immunodeficiency, immunomodulation, autoimmune diseases, allergies, wound healing, sive behavior, drug 20 resistance, addiction, psychosis, anorexia, cachexia, post-traumatic stress syndrome, postsurgical bone fracture, medical catabolism, major psychotic depression, mild cognitive impairment, psychosis, dementia, lycemia, stress disorders, ychotic d weight gain, delirium, cognitive impairment in depressed patients, cognitive deterioration in individuals with Down's syndrome, sis associated with interferon-alpha therapy, 25 chronic pain, pain associated with gastroesophageal reflux disease, postpartum psychosis, (10249821_1):KZA postpartum depression, neurological disorders in premature infants, and migraine headaches.
19. The use of claim 17, in the manufacture of a medicament wherein the disorder or condition is selected from the group consisting of major psychotic depression, 5 stress ers and antipsychotic induced weight gain. Corcept eutics, Inc. By the Attorneys for the Applicant SPRUSON & FERGUSON Per: (10249821_1):KZA 821_1):KZA
NZ615883A 2011-03-18 2012-03-16 Pyrimidine cyclohexyl glucocorticoid receptor modulators NZ615883B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161454289P 2011-03-18 2011-03-18
US61/454,289 2011-03-18
PCT/US2012/029376 WO2012129074A1 (en) 2011-03-18 2012-03-16 Pyrimidine cyclohexyl glucocorticoid receptor modulators

Publications (2)

Publication Number Publication Date
NZ615883A NZ615883A (en) 2015-07-31
NZ615883B2 true NZ615883B2 (en) 2015-11-03

Family

ID=

Similar Documents

Publication Publication Date Title
US8906917B2 (en) Pyrimidine cyclohexyl glucocorticoid receptor modulators
US20230167111A1 (en) Octahydro fused azadecalin glucocorticoid receptor modulators
JP4958774B2 (en) Modified pyrimidine glucocorticoid receptor modulators
US20130225633A1 (en) Phenyl heterocycloalkyl glucocorticoid receptor modulators
NZ615883B2 (en) Pyrimidine cyclohexyl glucocorticoid receptor modulators